<?xml version="1.0"?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2015//EN" "http://www.ncbi.nlm.nih.gov/corehtml/query/DTD/pubmed_150101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">16112032</PMID>
        <DateCreated>
            <Year>2005</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2005</Year>
            <Month>12</Month>
            <Day>07</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0198-8859</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>66</Volume>
                    <Issue>7</Issue>
                    <PubDate>
                        <Year>2005</Year>
                        <Month>Jul</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Human immunology</Title>
                <ISOAbbreviation>Hum. Immunol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Hyper-IgE syndrome is not associated with defects in several candidate toll-like receptor pathway genes.</ArticleTitle>
            <Pagination>
                <MedlinePgn>842-7</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>The genetic basis of hyper-IgE syndrome (HIES), also known as Job syndrome, a primary immunodeficiency associated with recurrent skin and pulmonary infections, is unknown. We hypothesized that HIES is due to a defect in the Toll-like receptor signaling pathway. We used a whole blood cytokine assay to compare inflammatory responses to stimulation with specific Toll-like receptor (TLR) pathway agonists in four individuals with HIES and nine healthy controls. Production of tumor necrosis factor-alpha, interleukin (IL)-1beta, IL-6, and IL-12 was not impaired in response to stimulation with lipopolysaccharide, peptidoglycan, zymosan, lipoteichoic acid, Staphylococcus aureus, Escherichia coli, or Streptococcus pneumoniae. Interferon (IFN)-gamma was reduced in HIES subjects in response to each of these stimuli. We sequenced several candidate genes from the TLR pathway in HIES individuals to determine whether any mutations were associated with this syndrome. No novel mutations or polymorphisms were found in the coding regions of TLR1, TLR2, TLR6, MyD88, or TRAF6. In summary, although HIES individuals had an IFN-gamma secretion defect, they also produced normal levels of several TLR-regulated proinflammatory cytokines. No unique mutations or polymorphisms were observed in several candidate genes from the TLR pathway. Our studies do not support a role for a defective TLR response in HIES individuals.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Hawn</LastName>
                    <ForeName>Thomas R</ForeName>
                    <Initials>TR</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of Washington School of Medicine, Seattle, WA 98103-8904, USA. thawn@u.washington.edu</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ozinsky</LastName>
                    <ForeName>Adrian</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Williams</LastName>
                    <ForeName>Luke M</ForeName>
                    <Initials>LM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rodrigues</LastName>
                    <ForeName>Stephanie</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Clark</LastName>
                    <ForeName>April</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pham</LastName>
                    <ForeName>Uyenvy</ForeName>
                    <Initials>U</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hill</LastName>
                    <ForeName>Harry R</ForeName>
                    <Initials>HR</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ochs</LastName>
                    <ForeName>Hans</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Aderem</LastName>
                    <ForeName>Alan</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liles</LastName>
                    <ForeName>W Conrad</ForeName>
                    <Initials>WC</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>HL62995</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
                <PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Hum Immunol</MedlineTA>
            <NlmUniqueID>8010936</NlmUniqueID>
            <ISSNLinking>0198-8859</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D048868">Adaptor Proteins, Signal Transducing</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000943">Antigens, Differentiation</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007378">Interleukins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D008070">Lipopolysaccharides</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C507779">MYD88 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D053594">Myeloid Differentiation Factor 88</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D010457">Peptidoglycan</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C495342">TLR2 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C495368">TLR6 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D048029">TNF Receptor-Associated Factor 6</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D013682">Teichoic Acids</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D051194">Toll-Like Receptor 1</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D051195">Toll-Like Receptor 2</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D051216">Toll-Like Receptor 6</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D051193">Toll-Like Receptors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>56411-57-5</RegistryNumber>
                <NameOfSubstance UI="C009900">lipoteichoic acid</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>82115-62-6</RegistryNumber>
                <NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>9010-72-4</RegistryNumber>
                <NameOfSubstance UI="D015054">Zymosan</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D048868">Adaptor Proteins, Signal Transducing</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000943">Antigens, Differentiation</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001419">Bacteria</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007371">Interferon-gamma</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007378">Interleukins</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007589">Job Syndrome</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008070">Lipopolysaccharides</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D053594">Myeloid Differentiation Factor 88</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010457">Peptidoglycan</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011110">Polymorphism, Genetic</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011971">Receptors, Immunologic</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D048029">TNF Receptor-Associated Factor 6</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013682">Teichoic Acids</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051194">Toll-Like Receptor 1</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051195">Toll-Like Receptor 2</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051216">Toll-Like Receptor 6</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051193">Toll-Like Receptors</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014409">Tumor Necrosis Factor-alpha</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015054">Zymosan</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2005</Year>
                <Month>2</Month>
                <Day>7</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2005</Year>
                <Month>4</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2005</Year>
                <Month>4</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2005</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2005</Year>
                <Month>12</Month>
                <Day>13</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2005</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0198-8859(05)00089-3</ArticleId>
            <ArticleId IdType="doi">10.1016/j.humimm.2005.04.009</ArticleId>
            <ArticleId IdType="pubmed">16112032</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">22022523</PMID>
        <DateCreated>
            <Year>2011</Year>
            <Month>10</Month>
            <Day>24</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2012</Year>
            <Month>02</Month>
            <Day>17</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>10</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1932-6203</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>6</Volume>
                    <Issue>10</Issue>
                    <PubDate>
                        <Year>2011</Year>
                    </PubDate>
                </JournalIssue>
                <Title>PloS one</Title>
                <ISOAbbreviation>PLoS ONE</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Augmented atherogenesis in LDL receptor deficient mice lacking both macrophage ABCA1 and ApoE.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e26095</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0026095</ELocationID>
            <Abstract>
                <AbstractText Label="AIM" NlmCategory="OBJECTIVE">ABCA1 protects against atherosclerosis by facilitating cholesterol efflux from macrophage foam cells in the arterial wall to extracellular apolipoprotein (apo) A-I. In contrast to apoA-I, apoE is secreted by macrophages and can, like apoA-I, induce ABCA1-mediated cholesterol efflux. Yet, the combined effect of macrophage ABCA1 and apoE on lesion development is unexplored.</AbstractText>
                <AbstractText Label="METHODS AND RESULTS" NlmCategory="RESULTS">LDL receptor knockout (KO) mice were transplanted with bone marrow from ABCA1/apoE double KO (dKO) mice, their respective single KO's, and wild-type (WT) controls and were challenged with a high-fat/high-cholesterol diet for 9 weeks. In vitro cholesterol efflux experiments showed no differences between ABCA1 KO and dKO macrophages. The serum non-HDL/HDL ratio in dKO transplanted mice was 1.7-fold and 2.4-fold (p&lt;0.01) increased compared to WT and ABCA1 KO transplanted mice, respectively. The atherosclerotic lesion area in dKO transplanted animals (650±94×10(3) µm(2)), however, was 1.9-fold (p&lt;0.01) and 1.6-fold (p&lt;0.01) increased compared to single knockouts (ABCA1 KO: 341±20×10(3) µm(2); apoE KO: 402±78×10(3) µm(2), respectively) and 3.1-fold increased (p&lt;0.001) compared to WT (211±20×10(3) µm(2)). When normalized for serum cholesterol exposure, macrophage ABCA1 and apoE independently protected against atherosclerotic lesion development (p&lt;0.001). Moreover, hepatic expression levels of TNFα and IL-6 were highly induced in dKO transplanted animals (3.0-fold; p&lt;0.05, and 4.3-fold; p&lt;0.001, respectively). In agreement, serum IL-6 levels were also enhanced in ABCA1 KO transplanted mice (p&lt;0.05) and even further enhanced in dKO transplanted animals (3.1-fold as compared to ABCA1 KO transplanted animals; p&lt;0.05).</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Combined deletion of macrophage ABCA1 and apoE results in a defect in cholesterol efflux and, compared to ABCA1 KO transplanted mice, elevated serum total cholesterol levels. Importantly, these mice also suffer from enhanced systemic and hepatic inflammation, together resulting in the observed augmented atherosclerotic lesion development.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Lammers</LastName>
                    <ForeName>Bart</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Biopharmaceutics, Leiden/Amsterdam Center for Drug Research, Gorlaeus Laboratories, Leiden University, Leiden, The Netherlands. b.lammers@lacdr.leidenuniv.nl</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhao</LastName>
                    <ForeName>Ying</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hoekstra</LastName>
                    <ForeName>Menno</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hildebrand</LastName>
                    <ForeName>Reeni B</ForeName>
                    <Initials>RB</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ye</LastName>
                    <ForeName>Dan</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Meurs</LastName>
                    <ForeName>Illiana</ForeName>
                    <Initials>I</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Van Berkel</LastName>
                    <ForeName>Theo J C</ForeName>
                    <Initials>TJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Van Eck</LastName>
                    <ForeName>Miranda</ForeName>
                    <Initials>M</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2011</Year>
                <Month>10</Month>
                <Day>11</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>PLoS One</MedlineTA>
            <NlmUniqueID>101285081</NlmUniqueID>
            <ISSNLinking>1932-6203</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D064286">ATP Binding Cassette Transporter 1</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D002788">Cholesterol Esters</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D004041">Dietary Fats</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018836">Inflammation Mediators</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D008074">Lipoproteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011973">Receptors, LDL</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.1.1.34</RegistryNumber>
                <NameOfSubstance UI="D008071">Lipoprotein Lipase</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Atherosclerosis. 2000 May;150(1):71-80</RefSource>
                <PMID Version="1">10781637</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):7987-92</RefSource>
                <PMID Version="1">10884428</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 2000 Nov 3;275(44):34508-11</RefSource>
                <PMID Version="1">10918070</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Arterioscler Thromb Vasc Biol. 2001 Jan;21(1):13-27</RefSource>
                <PMID Version="1">11145929</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>FASEB J. 2001 Jul;15(9):1555-61</RefSource>
                <PMID Version="1">11427487</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Lipid Res. 2001 Jul;42(7):1125-33</RefSource>
                <PMID Version="1">11441141</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Arterioscler Thromb Vasc Biol. 2001 Sep;21(9):1464-9</RefSource>
                <PMID Version="1">11557673</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Arterioscler Thromb Vasc Biol. 2001 Dec;21(12):2019-25</RefSource>
                <PMID Version="1">11742879</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Arterioscler Thromb Vasc Biol. 2002 Apr 1;22(4):630-7</RefSource>
                <PMID Version="1">11950702</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 2002 Apr 30;99(9):6298-303</RefSource>
                <PMID Version="1">11972062</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochem Biophys Res Commun. 2004 Apr 23;317(1):223-9</RefSource>
                <PMID Version="1">15047172</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9774-9</RefSource>
                <PMID Version="1">15210959</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Anal Biochem. 1975 May 12;65(1-2):42-9</RefSource>
                <PMID Version="1">165752</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Anal Biochem. 1987 Apr;162(1):156-9</RefSource>
                <PMID Version="1">2440339</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Science. 1988 Apr 29;240(4852):622-30</RefSource>
                <PMID Version="1">3283935</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>N Engl J Med. 1989 Apr 20;320(16):1060-8</RefSource>
                <PMID Version="1">2648155</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ann Epidemiol. 1992 Jan-Mar;2(1-2):23-8</RefSource>
                <PMID Version="1">1342260</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Circulation. 1994 Aug;90(2):769-74</RefSource>
                <PMID Version="1">8044946</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 1997 Apr 29;94(9):4647-52</RefSource>
                <PMID Version="1">9114045</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Lipid Res. 1999 May;40(5):806-13</RefSource>
                <PMID Version="1">10224149</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Can J Biochem Physiol. 1959 Aug;37(8):911-7</RefSource>
                <PMID Version="1">13671378</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cell Metab. 2005 Feb;1(2):121-31</RefSource>
                <PMID Version="1">16054053</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Arterioscler Thromb Vasc Biol. 2006 Feb;26(2):242-9</RefSource>
                <PMID Version="1">16373607</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Arterioscler Thromb Vasc Biol. 2006 Apr;26(4):929-34</RefSource>
                <PMID Version="1">16456089</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Arterioscler Thromb Vasc Biol. 2006 May;26(5):1177-83</RefSource>
                <PMID Version="1">16484594</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Curr Opin Lipidol. 2006 Jun;17(3):247-57</RefSource>
                <PMID Version="1">16680029</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Arterioscler Thromb Vasc Biol. 2006 Oct;26(10):2295-300</RefSource>
                <PMID Version="1">16857950</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Arterioscler Thromb Vasc Biol. 2008 Feb;28(2):258-64</RefSource>
                <PMID Version="1">18006857</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Atherosclerosis. 2009 Aug;205(2):420-6</RefSource>
                <PMID Version="1">19217108</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Intern Med. 2010 Dec;268(6):567-77</RefSource>
                <PMID Version="1">21091808</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Arterioscler Thromb Vasc Biol. 2011 Jan;31(1):74-80</RefSource>
                <PMID Version="1">20966401</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D064286">ATP Binding Cassette Transporter 1</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018528">ATP-Binding Cassette Transporters</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001057">Apolipoproteins E</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000172">deficiency</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D050197">Atherosclerosis</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016026">Bone Marrow Transplantation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002788">Cholesterol Esters</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016207">Cytokines</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004041">Dietary Fats</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005247">Feeding Behavior</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015971">Gene Expression Regulation, Enzymologic</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018836">Inflammation Mediators</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008071">Lipoprotein Lipase</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008074">Lipoproteins</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008099">Liver</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000201">enzymology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008264">Macrophages</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008810">Mice, Inbred C57BL</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018345">Mice, Knockout</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012333">RNA, Messenger</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011973">Receptors, LDL</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000172">deficiency</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013154">Spleen</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">PMC3191178</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2011</Year>
                <Month>6</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2011</Year>
                <Month>9</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2011</Year>
                <Month>10</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2011</Year>
                <Month>10</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2011</Year>
                <Month>10</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2012</Year>
                <Month>2</Month>
                <Day>18</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0026095</ArticleId>
            <ArticleId IdType="pii">PONE-D-11-11145</ArticleId>
            <ArticleId IdType="pubmed">22022523</ArticleId>
            <ArticleId IdType="pmc">PMC3191178</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">3900471</PMID>
        <DateCreated>
            <Year>1985</Year>
            <Month>11</Month>
            <Day>05</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1985</Year>
            <Month>11</Month>
            <Day>05</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0047-1852</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>43</Volume>
                    <Issue>6</Issue>
                    <PubDate>
                        <Year>1985</Year>
                        <Month>Jun</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Nihon rinsho. Japanese journal of clinical medicine</Title>
                <ISOAbbreviation>Nippon Rinsho</ISOAbbreviation>
            </Journal>
            <ArticleTitle>[Toxic hepatitis induced by steroids].</ArticleTitle>
            <Pagination>
                <MedlinePgn>1180-6</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Yamanaka</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sano</LastName>
                    <ForeName>N</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Itokazu</LastName>
                    <ForeName>K</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yokote</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Torii</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Miyake</LastName>
                    <ForeName>K</ForeName>
                    <Initials>K</Initials>
                </Author>
            </AuthorList>
            <Language>jpn</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>JAPAN</Country>
            <MedlineTA>Nihon Rinsho</MedlineTA>
            <NlmUniqueID>0420546</NlmUniqueID>
            <ISSNLinking>0047-1852</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D045930">Anabolic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000728">Androgens</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D001647">Bile Acids and Salts</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D003270">Contraceptive Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D004967">Estrogens</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D012739">Gonadal Steroid Hormones</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>9PHQ9Y1OLM</RegistryNumber>
                <NameOfSubstance UI="D011239">Prednisolone</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>V27W9254FZ</RegistryNumber>
                <NameOfSubstance UI="D003348">Cortisone</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>WI4X0X7BPJ</RegistryNumber>
                <NameOfSubstance UI="D006854">Hydrocortisone</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D045930">Anabolic Agents</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000728">Androgens</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001647">Bile Acids and Salts</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003270">Contraceptive Agents</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003348">Cortisone</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006224">Cricetinae</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D056486">Drug-Induced Liver Injury</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004967">Estrogens</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005938">Glucocorticoids</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012739">Gonadal Steroid Hormones</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006854">Hydrocortisone</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008113">Liver Neoplasms</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011239">Prednisolone</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <NumberOfReferences>18</NumberOfReferences>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1985</Year>
                <Month>6</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1985</Year>
                <Month>6</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1985</Year>
                <Month>6</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">3900471</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">14745880</PMID>
        <DateCreated>
            <Year>2004</Year>
            <Month>01</Month>
            <Day>27</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2004</Year>
            <Month>02</Month>
            <Day>19</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0008-543X</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>100</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2004</Year>
                        <Month>Feb</Month>
                        <Day>1</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Cancer</Title>
                <ISOAbbreviation>Cancer</ISOAbbreviation>
            </Journal>
            <ArticleTitle>High-dose tamoxifen and sulindac as first-line treatment for desmoid tumors.</ArticleTitle>
            <Pagination>
                <MedlinePgn>612-20</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Desmoid tumors are mesenchymal nonmetastasizing neoplasms. Although rare in the general population, they are a common extracolonic manifestation of familial adenomatous polyposis (FAP). Because of high tumor recurrence rates, surgery has been less than satisfactory in the treatment of desmoid tumors. In the current study, high doses of tamoxifen in combination with sulindac were used to treat severe desmoid tumors to avoid surgery.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Since 1992, 25 patients at Heinrich Heine University (Dusseldorf, Germany) were treated with a combination of tamoxifen and sulindac. In the current study, 17 patients with FAP-associated and 8 patients with sporadic desmoid tumors received 120 mg of tamoxifen and 300 mg of sulindac daily. Every 6 months, the protracted course of desmoid growth was measured by computed tomography and/or magnetic resonance imaging scans. Tumor responses were characterized as progressive disease, stable disease (SD), partial regression (PR), and complete regression (CR).</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the group of patients who received tamoxifen and sulindac as a primary treatment, all three patients with sporadic desmoid tumors demonstrated cessation of growth, and 10 of the 13 patients with FAP-associated tumors achieved either a PR or CR. In the sporadic desmoid tumor group, eight of nine patients developed tumor recurrences after undergoing surgery at other institutions. Of these, two patients had SD and two patients had a PR to CR.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The patients with desmoid tumors who were managed conservatively with high-dose tamoxifen and sulindac had the best outcome. Desmoid tumor recurrence after surgery was high and in the FAP-associated tumor group, therapy with tamoxifen and sulindac was found to be less successful. Based on this experience, the authors recommended high-dose tamoxifen and sulindac as the primary treatment for patients with FAP-associated desmoid tumors. However, to our knowledge, the best approach after surgical intervention for patients with sporadic desmoid tumors remains to be determined.</AbstractText>
                <CopyrightInformation>Copyright 2003 American Cancer Society.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Hansmann</LastName>
                    <ForeName>Anika</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of General Surgery and Traumatology, Heinrich Heine University, Duesseldorf, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Adolph</LastName>
                    <ForeName>Claudia</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Vogel</LastName>
                    <ForeName>Tilmann</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Unger</LastName>
                    <ForeName>Andreas</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Moeslein</LastName>
                    <ForeName>Gabriela</ForeName>
                    <Initials>G</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D003160">Comparative Study</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Cancer</MedlineTA>
            <NlmUniqueID>0374236</NlmUniqueID>
            <ISSNLinking>0008-543X</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000894">Anti-Inflammatory Agents, Non-Steroidal</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018931">Antineoplastic Agents, Hormonal</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>094ZI81Y45</RegistryNumber>
                <NameOfSubstance UI="D013629">Tamoxifen</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>184SNS8VUH</RegistryNumber>
                <NameOfSubstance UI="D013467">Sulindac</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>Cancer. 2004 Aug 1;101(3):652; author reply 653</RefSource>
                <PMID Version="1">15274082</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000008">Abdominal Neoplasms</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000894">Anti-Inflammatory Agents, Non-Steroidal</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018931">Antineoplastic Agents, Hormonal</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000971">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001707">Biopsy, Needle</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015331">Cohort Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004334">Drug Administration Schedule</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018221">Fibromatosis, Abdominal</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005500">Follow-Up Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009364">Neoplasm Recurrence, Local</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009367">Neoplasm Staging</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012189">Retrospective Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018570">Risk Assessment</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013467">Sulindac</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016019">Survival Analysis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013629">Tamoxifen</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2004</Year>
                <Month>1</Month>
                <Day>28</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2004</Year>
                <Month>2</Month>
                <Day>20</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2004</Year>
                <Month>1</Month>
                <Day>28</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">14745880</ArticleId>
            <ArticleId IdType="doi">10.1002/cncr.11937</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">17517692</PMID>
        <DateCreated>
            <Year>2007</Year>
            <Month>07</Month>
            <Day>02</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2007</Year>
            <Month>09</Month>
            <Day>14</Day>
        </DateCompleted>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">0964-6906</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>16</Volume>
                    <Issue>14</Issue>
                    <PubDate>
                        <Year>2007</Year>
                        <Month>Jul</Month>
                        <Day>15</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Human molecular genetics</Title>
                <ISOAbbreviation>Hum. Mol. Genet.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Left-sided embryonic expression of the BCL-6 corepressor, BCOR, is required for vertebrate laterality determination.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1773-82</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Oculofaciocardiodental (OFCD) syndrome is an X-linked male lethal condition encompassing cardiac septal defects, as well as ocular and dental anomalies. The gene mutated in OFCD syndrome, the BCL-6 corepressor (BCOR), is part of a transcriptional repression complex whose transcriptional targets remain largely unknown. We reviewed cases of OFCD syndrome and identified patients exhibiting defective lateralization including dextrocardia, asplenia and intestinal malrotation, suggesting that BCOR is required in normal laterality determination. To study the function of BCOR, we used morpholino oligonucleotides (MOs) to knockdown expression of xtBcor in Xenopus tropicalis, thus creating an animal model for OFCD syndrome. The resulting tadpoles had cardiac and ocular features characteristic of OFCD syndrome. Reversed cardiac orientation and disorganized gut patterning were seen when MOs were injected into the left side of embryos, demonstrating a left-sided requirement for xtBcor in lateral determination in Xenopus. Ocular defects displayed no left-right bias and included anterior and posterior segment disorders such as microphthalmia and coloboma. Expression of xtPitx2c was shown to be downregulated when xtBcor was depleted. This identifies a pathway in which xtBcor is required for lateral specification, a process intrinsically linked to correct cardiac septal development.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Hilton</LastName>
                    <ForeName>Emma N</ForeName>
                    <Initials>EN</Initials>
                    <AffiliationInfo>
                        <Affiliation>Academic Unit of Medical Genetics and Regional Genetic Service, St Mary's Hospital, Manchester, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Manson</LastName>
                    <ForeName>Forbes D C</ForeName>
                    <Initials>FD</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Urquhart</LastName>
                    <ForeName>Jill E</ForeName>
                    <Initials>JE</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Johnston</LastName>
                    <ForeName>Jennifer J</ForeName>
                    <Initials>JJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Slavotinek</LastName>
                    <ForeName>Anne M</ForeName>
                    <Initials>AM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hedera</LastName>
                    <ForeName>Peter</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Stattin</LastName>
                    <ForeName>Eva-Lena</ForeName>
                    <Initials>EL</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nordgren</LastName>
                    <ForeName>Ann</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Biesecker</LastName>
                    <ForeName>Leslie G</ForeName>
                    <Initials>LG</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Black</LastName>
                    <ForeName>Graeme C M</ForeName>
                    <Initials>GC</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>GR067443MA</GrantID>
                    <Agency>Wellcome Trust</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2007</Year>
                <Month>05</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Hum Mol Genet</MedlineTA>
            <NlmUniqueID>9208958</NlmUniqueID>
            <ISSNLinking>0964-6906</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C084103">BCL6 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C411984">BCOR protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011518">Proto-Oncogene Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D012097">Repressor Proteins</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D019521">Body Patterning</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D041321">Chromosomes, Human, X</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D019465">Craniofacial Abnormalities</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004268">DNA-Binding Proteins</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005128">Eye Diseases</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D018507">Gene Expression Regulation, Developmental</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006321">Heart</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000196">embryology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D009154">Mutation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011518">Proto-Oncogene Proteins</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000096">biosynthesis</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012097">Repressor Proteins</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000096">biosynthesis</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013577">Syndrome</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014018">Tissue Distribution</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014981">Xenopus</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2007</Year>
                <Month>5</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2007</Year>
                <Month>5</Month>
                <Day>23</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2007</Year>
                <Month>9</Month>
                <Day>15</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2007</Year>
                <Month>5</Month>
                <Day>23</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">ddm125</ArticleId>
            <ArticleId IdType="doi">10.1093/hmg/ddm125</ArticleId>
            <ArticleId IdType="pubmed">17517692</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">8902272</PMID>
        <DateCreated>
            <Year>1997</Year>
            <Month>02</Month>
            <Day>20</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1997</Year>
            <Month>02</Month>
            <Day>20</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>11</Month>
            <Day>20</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0893-228X</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>9</Volume>
                    <Issue>7</Issue>
                    <PubDate>
                        <MedlineDate>1996 Oct-Nov</MedlineDate>
                    </PubDate>
                </JournalIssue>
                <Title>Chemical research in toxicology</Title>
                <ISOAbbreviation>Chem. Res. Toxicol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Human cytochrome P450 2E1 is a major autoantigen associated with halothane hepatitis.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1159-66</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Autoantibodies against specific human cytochrome P450s have been found in the sera of patients suffering from a variety of diseases, including those caused by drugs. In the cases of tienilic acid- and dihydralazine-induced hepatitis, patients have serum autoantibodies directed against cytochromes P450 2C9 and P450 1A2, respectively. In the present study, we have found that 25 of 56 (45%) patients diagnosed with halothane hepatitis have autoantibodies that react with human cytochrome P450 2E1 that was purified from a baculovirus expression system. The autoantibodies inhibited the activity of cytochrome P450 2E1 and appeared to be directed against mainly conformational epitopes. In addition, because cytochrome P450 2E1 became trifluoroacetylated when it oxidatively metabolized halothane, it is possible that the covalently altered form of cytochrome P450 2E1 may be able to bypass the immunologic tolerance that normally exists against cytochrome P450 2E1. A similar mechanism may explain the formation of autoantibodies that have been found against other cellular targets of the reactive trifluoroacetyl chloride metabolite of halothane.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Bourdi</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Molecular and Cellular Toxicology Section, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>W</ForeName>
                    <Initials>W</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Peter</LastName>
                    <ForeName>R M</ForeName>
                    <Initials>RM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Martin</LastName>
                    <ForeName>J L</ForeName>
                    <Initials>JL</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Buters</LastName>
                    <ForeName>J T</ForeName>
                    <Initials>JT</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nelson</LastName>
                    <ForeName>S D</ForeName>
                    <Initials>SD</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pohl</LastName>
                    <ForeName>L R</ForeName>
                    <Initials>LR</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>ES 02728</GrantID>
                    <Acronym>ES</Acronym>
                    <Agency>NIEHS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>GM 32165</GrantID>
                    <Acronym>GM</Acronym>
                    <Agency>NIGMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
                <PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>Chem Res Toxicol</MedlineTA>
            <NlmUniqueID>8807448</NlmUniqueID>
            <ISSNLinking>0893-228X</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D001324">Autoantigens</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>284SYP0193</RegistryNumber>
                <NameOfSubstance UI="D005461">Fluorine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.14.13.-</RegistryNumber>
                <NameOfSubstance UI="D019392">Cytochrome P-450 CYP2E1</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>UQT9G45D1P</RegistryNumber>
                <NameOfSubstance UI="D006221">Halothane</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000107">Acetylation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001323">Autoantibodies</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001324">Autoantigens</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D019392">Cytochrome P-450 CYP2E1</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D056486">Drug-Induced Liver Injury</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005461">Fluorine</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006221">Halothane</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1996</Year>
                <Month>10</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1996</Year>
                <Month>10</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1996</Year>
                <Month>10</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">8902272</ArticleId>
            <ArticleId IdType="doi">10.1021/tx960083q</ArticleId>
            <ArticleId IdType="pii">tx960083q</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">7819850</PMID>
        <DateCreated>
            <Year>1995</Year>
            <Month>02</Month>
            <Day>10</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1995</Year>
            <Month>02</Month>
            <Day>10</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0959-8138</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>309</Volume>
                    <Issue>6966</Issue>
                    <PubDate>
                        <Year>1994</Year>
                        <Month>Nov</Month>
                        <Day>26</Day>
                    </PubDate>
                </JournalIssue>
                <Title>BMJ (Clinical research ed.)</Title>
                <ISOAbbreviation>BMJ</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Acute hemiparesis associated with ciprofloxacin.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1411</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Rosolen</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Paediatrics, University of Padua, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Drigo</LastName>
                    <ForeName>P</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zanesco</LastName>
                    <ForeName>L</ForeName>
                    <Initials>L</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>ENGLAND</Country>
            <MedlineTA>BMJ</MedlineTA>
            <NlmUniqueID>8900488</NlmUniqueID>
            <ISSNLinking>0959-535X</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>5E8K9I0O4U</RegistryNumber>
                <NameOfSubstance UI="D002939">Ciprofloxacin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Infection. 1991 Jul-Aug;19(4):289-96</RefSource>
                <PMID Version="1">1917049</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Lancet. 1991 Jul 27;338(8761):259</RefSource>
                <PMID Version="1">1676814</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000208">Acute Disease</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002939">Ciprofloxacin</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003389">Cranial Nerve Diseases</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006429">Hemiplegia</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D054198">Precursor Cell Lymphoblastic Leukemia-Lymphoma</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">PMC2541354</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1994</Year>
                <Month>11</Month>
                <Day>26</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1994</Year>
                <Month>11</Month>
                <Day>26</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1994</Year>
                <Month>11</Month>
                <Day>26</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">7819850</ArticleId>
            <ArticleId IdType="pmc">PMC2541354</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">6884225</PMID>
        <DateCreated>
            <Year>1983</Year>
            <Month>10</Month>
            <Day>28</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1983</Year>
            <Month>10</Month>
            <Day>28</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0012-0472</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>108</Volume>
                    <Issue>37</Issue>
                    <PubDate>
                        <Year>1983</Year>
                        <Month>Sep</Month>
                        <Day>16</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Deutsche medizinische Wochenschrift (1946)</Title>
                <ISOAbbreviation>Dtsch. Med. Wochenschr.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>[Cutaneous coumarin necrosis of the breast].</ArticleTitle>
            <Pagination>
                <MedlinePgn>1399-402</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>In a 62-year-old female patient petechial haemorrhages of the right breast were observed after the 4th day of treatment with phenprocoumon. Within a few hours large cutaneous necroses developed. Histology showed lymphocytic vasculitis with vessel wall destruction and erythrocytic extravasates as well as necrobiotic changes of the middle and lower corium. High-dosage treatment with prednisolone was started after withdrawal of phenprocoumon. Progression of the necrosis to the left breast could be prevented. However, necrosis of the haemorrhagic area of the right breast could not be arrested. Aetiology and pathomechanisms of coumarin-induced necrosis have to date not been ascertained. Allergic precipitating mechanisms probably were of no importance in our patient.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Luderschmidt</LastName>
                    <ForeName>C</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gutschow</LastName>
                    <ForeName>K</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Baumeister</LastName>
                    <ForeName>R G</ForeName>
                    <Initials>RG</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Albrich</LastName>
                    <ForeName>W</ForeName>
                    <Initials>W</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Eiermann</LastName>
                    <ForeName>W</ForeName>
                    <Initials>W</Initials>
                </Author>
            </AuthorList>
            <Language>ger</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D004740">English Abstract</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <VernacularTitle>Kutane Cumarinnekrose der Brust.</VernacularTitle>
        </Article>
        <MedlineJournalInfo>
            <Country>GERMANY, WEST</Country>
            <MedlineTA>Dtsch Med Wochenschr</MedlineTA>
            <NlmUniqueID>0006723</NlmUniqueID>
            <ISSNLinking>0012-0472</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D015110">4-Hydroxycoumarins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>7LXU5N7ZO5</RegistryNumber>
                <NameOfSubstance UI="D005665">Furosemide</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>80061L1WGD</RegistryNumber>
                <NameOfSubstance UI="D002927">Cimetidine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>9PHQ9Y1OLM</RegistryNumber>
                <NameOfSubstance UI="D011239">Prednisolone</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>Q08SIO485D</RegistryNumber>
                <NameOfSubstance UI="D010644">Phenprocoumon</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>Q1J152VB1P</RegistryNumber>
                <NameOfSubstance UI="D001964">Bromhexine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015110">4-Hydroxycoumarins</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001941">Breast Diseases</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001964">Bromhexine</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002927">Cimetidine</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005665">Furosemide</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009336">Necrosis</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010644">Phenprocoumon</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011239">Prednisolone</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011655">Pulmonary Embolism</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014581">Urticaria</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014657">Vasculitis</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1983</Year>
                <Month>9</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1983</Year>
                <Month>9</Month>
                <Day>16</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1983</Year>
                <Month>9</Month>
                <Day>16</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">6884225</ArticleId>
            <ArticleId IdType="doi">10.1055/s-2008-1069757</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">17503014</PMID>
        <DateCreated>
            <Year>2007</Year>
            <Month>08</Month>
            <Day>23</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2008</Year>
            <Month>02</Month>
            <Day>26</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">0342-4642</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>33</Volume>
                    <Issue>9</Issue>
                    <PubDate>
                        <Year>2007</Year>
                        <Month>Sep</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Intensive care medicine</Title>
                <ISOAbbreviation>Intensive Care Med</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Adenosine for salbutamol-induced supraventricular tachycardia.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1676</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Trachsel</LastName>
                    <ForeName>Daniel</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Newth</LastName>
                    <ForeName>Christopher J L</ForeName>
                    <Initials>CJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hammer</LastName>
                    <ForeName>Juerg</ForeName>
                    <Initials>J</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016422">Letter</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2007</Year>
                <Month>05</Month>
                <Day>15</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Intensive Care Med</MedlineTA>
            <NlmUniqueID>7704851</NlmUniqueID>
            <ISSNLinking>0342-4642</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000889">Anti-Arrhythmia Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D001993">Bronchodilator Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>K72T3FS567</RegistryNumber>
                <NameOfSubstance UI="D000241">Adenosine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>QF8SVZ843E</RegistryNumber>
                <NameOfSubstance UI="D000420">Albuterol</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000241">Adenosine</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000420">Albuterol</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000889">Anti-Arrhythmia Agents</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001249">Asthma</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001993">Bronchodilator Agents</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013617">Tachycardia, Supraventricular</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2006</Year>
                <Month>12</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2007</Year>
                <Month>4</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2007</Year>
                <Month>5</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2007</Year>
                <Month>5</Month>
                <Day>16</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2008</Year>
                <Month>2</Month>
                <Day>27</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2007</Year>
                <Month>5</Month>
                <Day>16</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00134-007-0673-4</ArticleId>
            <ArticleId IdType="pubmed">17503014</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">846520</PMID>
        <DateCreated>
            <Year>1977</Year>
            <Month>05</Month>
            <Day>12</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1977</Year>
            <Month>05</Month>
            <Day>12</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0028-4793</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>296</Volume>
                    <Issue>16</Issue>
                    <PubDate>
                        <Year>1977</Year>
                        <Month>Apr</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>The New England journal of medicine</Title>
                <ISOAbbreviation>N. Engl. J. Med.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Clofibrate-induced muscle damage with myoglobinuria and cardiomyopathy.</ArticleTitle>
            <Pagination>
                <MedlinePgn>942</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Smals</LastName>
                    <ForeName>A G</ForeName>
                    <Initials>AG</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Beex</LastName>
                    <ForeName>L V</ForeName>
                    <Initials>LV</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kloppenborg</LastName>
                    <ForeName>P W</ForeName>
                    <Initials>PW</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016422">Letter</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>N Engl J Med</MedlineTA>
            <NlmUniqueID>0255562</NlmUniqueID>
            <ISSNLinking>0028-4793</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>HPN91K7FU3</RegistryNumber>
                <NameOfSubstance UI="D002994">Clofibrate</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009202">Cardiomyopathies</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002994">Clofibrate</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003919">Diabetes Insipidus</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009135">Muscular Diseases</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009212">Myoglobinuria</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1977</Year>
                <Month>4</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1977</Year>
                <Month>4</Month>
                <Day>21</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1977</Year>
                <Month>4</Month>
                <Day>21</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">846520</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
        <PMID Version="1">18193104</PMID>
        <DateCreated>
            <Year>2008</Year>
            <Month>01</Month>
            <Day>14</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2011</Year>
            <Month>07</Month>
            <Day>14</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>05</Month>
            <Day>23</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0912-0009</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>41</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>2007</Year>
                        <Month>Sep</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of clinical biochemistry and nutrition</Title>
                <ISOAbbreviation>J Clin Biochem Nutr</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Healing Properties of Some Indian Medicinal Plants against Indomethacin-Induced Gastric Ulceration of Rats.</ArticleTitle>
            <Pagination>
                <MedlinePgn>106-14</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.3164/jcbn.2007015</ELocationID>
            <Abstract>
                <AbstractText>The healing activity of the ethanol extracts of Piper betel, Emblica officinalis, Terminalia bellerica, and Terminalia chebula against the indomethacin-induced stomach ulceration has been studied and compared with that of misoprostol. Compared to autohealing, all the drugs accelerated the healing process, albeit to different extents. The relative healing activities of the extracts was P. betel&gt;E. officinalis&gt;T. bellerica~T. chebula, that correlated well with their in vivo antioxidant and mucin augmenting activities. The excellent healing activity of the extracts of P. betel and E. officinalis indicated a major role of mucin protection and regeneration in the healing of nonsteroidal anti-inflammatory drugs mediated stomach ulceration.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Bhattacharya</LastName>
                    <ForeName>Sayanti</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biochemistry, Dr. B.C. Roy Post Graduate Institute of Basic Medical Sciences and IPGMERR, 244B, Acharya Jagadish Chandra Bose Road, Kolkata - 700 020, India.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chaudhuri</LastName>
                    <ForeName>Susri R</ForeName>
                    <Initials>SR</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chattopadhyay</LastName>
                    <ForeName>Subrata</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bandyopadhyay</LastName>
                    <ForeName>Sandip K</ForeName>
                    <Initials>SK</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Japan</Country>
            <MedlineTA>J Clin Biochem Nutr</MedlineTA>
            <NlmUniqueID>8700907</NlmUniqueID>
            <ISSNLinking>0912-0009</ISSNLinking>
        </MedlineJournalInfo>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Digestion. 1999 Nov-Dec;60(6):538-43</RefSource>
                <PMID Version="1">10545723</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Free Radic Biol Med. 1999 Jan;26(1-2):193-201</RefSource>
                <PMID Version="1">9890654</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Med. 2001 Jan 8;110(1A):33S-37S</RefSource>
                <PMID Version="1">11165994</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ann Clin Biochem. 2001 Nov;38(Pt 6):694-700</RefSource>
                <PMID Version="1">11732653</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Phytomedicine. 2002 Mar;9(2):171-4</RefSource>
                <PMID Version="1">11995952</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Ethnopharmacol. 2002 Sep;82(1):1-9</RefSource>
                <PMID Version="1">12169398</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Phytomedicine. 2002 Sep;9(6):515-22</RefSource>
                <PMID Version="1">12403160</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 2003 Mar 28;278(13):10993-1001</RefSource>
                <PMID Version="1">12529378</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Indian J Exp Biol. 2000 Sep;38(9):877-80</RefSource>
                <PMID Version="1">12561944</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Phytomedicine. 2004 Sep;11(6):530-8</RefSource>
                <PMID Version="1">15500265</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Radiat Res. 2005 Jun;46(2):165-71</RefSource>
                <PMID Version="1">15988134</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Arch Biochem Biophys. 1992 Feb 14;293(1):103-9</RefSource>
                <PMID Version="1">1731626</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Methods Enzymol. 1990;186:407-21</RefSource>
                <PMID Version="1">2233308</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Med. 1989 Jun 9;86(6A):23-31</RefSource>
                <PMID Version="1">2735333</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Fortschr Med. 1986 Dec 9;104(3):918-20</RefSource>
                <PMID Version="1">2881864</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 1969 Nov 25;244(22):6049-55</RefSource>
                <PMID Version="1">5389100</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Annu Rev Biochem. 1984;53:749-90</RefSource>
                <PMID Version="1">6206782</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Indian J Exp Biol. 1995 Oct;33(10):752-6</RefSource>
                <PMID Version="1">8575807</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Gastroenterol. 1995;21 Suppl 1:S82-6</RefSource>
                <PMID Version="1">8774996</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pharmacol Res. 1997 Oct;36(4):315-21</RefSource>
                <PMID Version="1">9425622</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Ethnopharmacol. 2000 May;70(2):171-6</RefSource>
                <PMID Version="1">10771207</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <OtherID Source="NLM">PMC2170955</OtherID>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Indian medicinal plants</Keyword>
            <Keyword MajorTopicYN="N">antioxidant</Keyword>
            <Keyword MajorTopicYN="N">indomethacin</Keyword>
            <Keyword MajorTopicYN="N">mucin</Keyword>
            <Keyword MajorTopicYN="N">stomach ulcer</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2006</Year>
                <Month>9</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2007</Year>
                <Month>1</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2008</Year>
                <Month>1</Month>
                <Day>15</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2008</Year>
                <Month>1</Month>
                <Day>15</Day>
                <Hour>9</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2008</Year>
                <Month>1</Month>
                <Day>15</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.3164/jcbn.2007015</ArticleId>
            <ArticleId IdType="pubmed">18193104</ArticleId>
            <ArticleId IdType="pmc">PMC2170955</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">7819852</PMID>
        <DateCreated>
            <Year>1995</Year>
            <Month>02</Month>
            <Day>10</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1995</Year>
            <Month>02</Month>
            <Day>10</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0959-8138</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>309</Volume>
                    <Issue>6966</Issue>
                    <PubDate>
                        <Year>1994</Year>
                        <Month>Nov</Month>
                        <Day>26</Day>
                    </PubDate>
                </JournalIssue>
                <Title>BMJ (Clinical research ed.)</Title>
                <ISOAbbreviation>BMJ</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Sleep disturbance in children treated with ofloxacin.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1411</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Upton</LastName>
                    <ForeName>C</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Norfolk and Norwich Hospital.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>ENGLAND</Country>
            <MedlineTA>BMJ</MedlineTA>
            <NlmUniqueID>8900488</NlmUniqueID>
            <ISSNLinking>0959-535X</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>A4P49JAZ9H</RegistryNumber>
                <NameOfSubstance UI="D015242">Ofloxacin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Lancet. 1991 Sep 21;338(8769):725-6</RefSource>
                <PMID Version="1">1679870</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Antimicrob Chemother. 1987 Oct;20(4):585-94</RefSource>
                <PMID Version="1">3479420</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002648">Child</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003550">Cystic Fibrosis</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015242">Ofloxacin</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009894">Opportunistic Infections</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011552">Pseudomonas Infections</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012893">Sleep Disorders</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">PMC2541326</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1994</Year>
                <Month>11</Month>
                <Day>26</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1994</Year>
                <Month>11</Month>
                <Day>26</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1994</Year>
                <Month>11</Month>
                <Day>26</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">7819852</ArticleId>
            <ArticleId IdType="pmc">PMC2541326</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">18722515</PMID>
        <DateCreated>
            <Year>2010</Year>
            <Month>10</Month>
            <Day>20</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2011</Year>
            <Month>03</Month>
            <Day>03</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1873-2747</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>77</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2008</Year>
                        <Month>Nov</Month>
                        <Day>25</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Brain research bulletin</Title>
                <ISOAbbreviation>Brain Res. Bull.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Effects of chronic treatment with levetiracetam on hippocampal field responses after pilocarpine-induced status epilepticus in rats.</ArticleTitle>
            <Pagination>
                <MedlinePgn>282-5</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.brainresbull.2008.07.006</ELocationID>
            <Abstract>
                <AbstractText>Levetiracetam (Keppra) is a new generation antiepileptic drug characterized by a unique profile of activity in experimental models of epilepsy. It also has a distinct binding site in the brain, i.e. the synaptic vesicle protein type 2 (SV2A). Levetiracetam has been reported to have antiepileptogenic and disease-modifying properties. In the present study the effects of chronic treatment with levetiracetam were assessed in rats that sustained pilocarpine-induced status epilepticus (SE). Hippocampal field potentials were recorded in vivo in anesthetized animals after 3-day washout period that followed 21-day treatment with different doses of levetiracetam (50, 150 or 300 mg/kg/day) administered via ALZET osmotic mini-pumps. Vehicle treated rats together with naive animals (not subjected to SE) were used as control groups. Chronic treatment with levetiracetam yielded clinically relevant plasma concentrations throughout the experiment with complete washout of the drug 3 days after treatment cessation. At this point in time post-SE rats chronically treated with vehicle developed clear signs of hippocampal hyperexcitability, i.e. increased amplitude of population spike (PS) recorded in the dentate gyrus and reduced paired-pulse inhibition in the CA1 area. Levetiracetam treatment dose-dependently counteracted these long-term effects of pilocarpine-induced SE. Furthermore, at the dose of 300 mg/kg/day levetiracetam restored these parameters back to control level. The present results indicate that chronic treatment with levetiracetam completely inhibits the development of hippocampal hyperexcitability following pilocarpine-induced SE.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Margineanu</LastName>
                    <ForeName>Doru-Georg</ForeName>
                    <Initials>DG</Initials>
                    <AffiliationInfo>
                        <Affiliation>UCB PHARMA SA, CNS Research, B-1420 Braine-l'Alleud, Belgium.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Matagne</LastName>
                    <ForeName>Alain</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kaminski</LastName>
                    <ForeName>Rafal M</ForeName>
                    <Initials>RM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Klitgaard</LastName>
                    <ForeName>Henrik</ForeName>
                    <Initials>H</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2008</Year>
                <Month>08</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Brain Res Bull</MedlineTA>
            <NlmUniqueID>7605818</NlmUniqueID>
            <ISSNLinking>0361-9230</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018721">Muscarinic Agonists</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>01MI4Q9DI3</RegistryNumber>
                <NameOfSubstance UI="D010862">Pilocarpine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>230447L0GL</RegistryNumber>
                <NameOfSubstance UI="C026098">etiracetam</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>ZH516LNZ10</RegistryNumber>
                <NameOfSubstance UI="D010889">Piracetam</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000927">Anticonvulsants</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D006624">Hippocampus</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D008564">Membrane Potentials</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018721">Muscarinic Agonists</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010862">Pilocarpine</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010889">Piracetam</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000031">analogs &amp; derivatives</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017207">Rats, Sprague-Dawley</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D013226">Status Epilepticus</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2008</Year>
                <Month>5</Month>
                <Day>28</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2008</Year>
                <Month>7</Month>
                <Day>8</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2008</Year>
                <Month>7</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2008</Year>
                <Month>8</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2008</Year>
                <Month>8</Month>
                <Day>30</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2011</Year>
                <Month>3</Month>
                <Day>4</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2008</Year>
                <Month>8</Month>
                <Day>30</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0361-9230(08)00261-X</ArticleId>
            <ArticleId IdType="doi">10.1016/j.brainresbull.2008.07.006</ArticleId>
            <ArticleId IdType="pubmed">18722515</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">5547575</PMID>
        <DateCreated>
            <Year>1971</Year>
            <Month>04</Month>
            <Day>26</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1971</Year>
            <Month>04</Month>
            <Day>26</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0007-1447</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>1</Volume>
                    <Issue>5748</Issue>
                    <PubDate>
                        <Year>1971</Year>
                        <Month>Mar</Month>
                        <Day>6</Day>
                    </PubDate>
                </JournalIssue>
                <Title>British medical journal</Title>
                <ISOAbbreviation>Br Med J</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Production of sinus arrest by lignocaine.</ArticleTitle>
            <Pagination>
                <MedlinePgn>537</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Lippestad</LastName>
                    <ForeName>C T</ForeName>
                    <Initials>CT</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Forfang</LastName>
                    <ForeName>K</ForeName>
                    <Initials>K</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>ENGLAND</Country>
            <MedlineTA>Br Med J</MedlineTA>
            <NlmUniqueID>0372673</NlmUniqueID>
            <ISSNLinking>0007-1447</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>7C0697DR9I</RegistryNumber>
                <NameOfSubstance UI="D001285">Atropine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>98PI200987</RegistryNumber>
                <NameOfSubstance UI="D008012">Lidocaine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am Heart J. 1965 Nov;70(5):713-5</RefSource>
                <PMID Version="1">5843826</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ann Intern Med. 1966 Jul;65(1):28-36</RefSource>
                <PMID Version="1">5936665</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Br Heart J. 1967 Jul;29(4):469-89</RefSource>
                <PMID Version="1">6029120</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Cardiol. 1969 Jun;23(6):769-70</RefSource>
                <PMID Version="1">5785155</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>South Med J. 1959 Jun;52(6):702-6</RefSource>
                <PMID Version="1">13659168</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Circulation. 1961 Oct;24:761-76</RefSource>
                <PMID Version="1">14451030</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Arch Intern Med. 1962 Sep;110:305-11</RefSource>
                <PMID Version="1">14451033</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Circulation. 1963 Oct;28:486-91</RefSource>
                <PMID Version="1">14068756</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001285">Atropine</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004562">Electrocardiography</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006323">Heart Arrest</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008012">Lidocaine</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012849">Sinoatrial Node</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">PMC1795286</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1971</Year>
                <Month>3</Month>
                <Day>6</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1971</Year>
                <Month>3</Month>
                <Day>6</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1971</Year>
                <Month>3</Month>
                <Day>6</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">5547575</ArticleId>
            <ArticleId IdType="pmc">PMC1795286</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">17503055</PMID>
        <DateCreated>
            <Year>2007</Year>
            <Month>11</Month>
            <Day>23</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2009</Year>
            <Month>02</Month>
            <Day>19</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1433-0350</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>24</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2008</Year>
                        <Month>Jan</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery</Title>
                <ISOAbbreviation>Childs Nerv Syst</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Neuroprotective effects of high-dose vs low-dose melatonin after blunt sciatic nerve injury.</ArticleTitle>
            <Pagination>
                <MedlinePgn>111-7</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Melatonin, the secretory product of the pineal gland, has potent antioxidant properties. The aim of this study was to compare the effects of low-dose (10 mg/kg) vs high-dose (50 mg/kg) melatonin on early lipid peroxidation levels and ultrastructural changes in experimental blunt sciatic nerve injury (SNI). We believe this to be the first study to assess the dose-dependent neuroprotective effects of melatonin after a blunt peripheral nerve injury.</AbstractText>
                <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Rats were randomly allocated into 5 groups of 10 animals each. The SNI only rats underwent a nerve injury procedure. The SNI plus vehicle group received SNI and intraperitoneal injection of vehicle (diluted ethanol) as a placebo. The SNI plus low-dose or high-dose melatonin groups received intraperitoneal melatonin at doses of 10 mg/kg or 50 mg/kg, respectively. Controls had no operation, melatonin or vehicle injection. SNI was induced by clamping the sciatic nerve at the upper border of the quadratus femoris for 2 min.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Sciatic nerve samples were harvested 6 h after nerve injury and processed for biochemical and ultrastructural analysis. Trauma increased the lipid peroxidation of the sciatic nerve by 3.6-fold (153.85 +/- 18.73 in SNI only vs 41.73 +/- 2.23 in control rats, P &lt; 0.01). Low (P = 0.02) and high (P &lt; 0.01) doses of melatonin attenuated the nerve lipid peroxidation by 25% and 57.25%, respectively (65.76 +/- 2.47 in high-dose vs 115.08 +/- 7.03 in low-dose melatonin groups).</AbstractText>
                <AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">Although low-dose melatonin reduced trauma-induced myelin breakdown and axonal changes in the sciatic nerve, high-dose melatonin almost entirely neutralized any ultrastructural changes.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our results suggest that melatonin, especially at a dose of 50 mg/kg, has a potent neuroprotective effect and can preserve peripheral neural fibers from lipid peroxidative damage after blunt trauma. With further investigations, we hope that these data may prove useful to clinicians who treat patients with nerve injuries.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Shokouhi</LastName>
                    <ForeName>Ghaffar</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Neurosurgery and Anatomy, Tabriz University of Medical Sciences, Tabriz, Iran.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tubbs</LastName>
                    <ForeName>R Shane</ForeName>
                    <Initials>RS</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shoja</LastName>
                    <ForeName>Mohammadali M</ForeName>
                    <Initials>MM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hadidchi</LastName>
                    <ForeName>Shahram</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ghorbanihaghjo</LastName>
                    <ForeName>Amir</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Roshangar</LastName>
                    <ForeName>Leila</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Farahani</LastName>
                    <ForeName>Ramin M</ForeName>
                    <Initials>RM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mesgari</LastName>
                    <ForeName>Mehran</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Oakes</LastName>
                    <ForeName>W Jerry</ForeName>
                    <Initials>WJ</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2007</Year>
                <Month>05</Month>
                <Day>15</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Germany</Country>
            <MedlineTA>Childs Nerv Syst</MedlineTA>
            <NlmUniqueID>8503227</NlmUniqueID>
            <ISSNLinking>0256-7040</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000975">Antioxidants</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>JL5DK93RCL</RegistryNumber>
                <NameOfSubstance UI="D008550">Melatonin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000704">Analysis of Variance</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000975">Antioxidants</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007274">Injections, Intraperitoneal</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015227">Lipid Peroxidation</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008550">Melatonin</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008854">Microscopy, Electron</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018696">Neuroprotective Agents</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017208">Rats, Wistar</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012584">Sciatic Nerve</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000293">injuries</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000648">ultrastructure</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020426">Sciatic Neuropathy</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013053">Spectrophotometry</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2007</Year>
                <Month>3</Month>
                <Day>30</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2007</Year>
                <Month>4</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2007</Year>
                <Month>5</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2007</Year>
                <Month>5</Month>
                <Day>16</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2009</Year>
                <Month>2</Month>
                <Day>20</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2007</Year>
                <Month>5</Month>
                <Day>16</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00381-007-0366-x</ArticleId>
            <ArticleId IdType="pubmed">17503055</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">1481877</PMID>
        <DateCreated>
            <Year>1993</Year>
            <Month>02</Month>
            <Day>09</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1993</Year>
            <Month>02</Month>
            <Day>09</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0250-8095</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>12</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>1992</Year>
                    </PubDate>
                </JournalIssue>
                <Title>American journal of nephrology</Title>
                <ISOAbbreviation>Am. J. Nephrol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Ciprofloxacin-induced acute interstitial nephritis.</ArticleTitle>
            <Pagination>
                <MedlinePgn>271-3</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Acute renal failure is a complication attributed to numerous medications. Few cases linked to the newer fluoroquinolones have been described. We report a case of acute interstitial nephritis confirmed by renal biopsy that developed in a patient within days of starting ciprofloxacin therapy. A review of the literature reveals common clinical manifestations of this rare adverse effect. Clinicians should be aware of this potential complication of ciprofloxacin use.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Bailey</LastName>
                    <ForeName>J R</ForeName>
                    <Initials>JR</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine, University of Virginia Medical Center, Charlottesville 22908.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Trott</LastName>
                    <ForeName>S A</ForeName>
                    <Initials>SA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Philbrick</LastName>
                    <ForeName>J T</ForeName>
                    <Initials>JT</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>SWITZERLAND</Country>
            <MedlineTA>Am J Nephrol</MedlineTA>
            <NlmUniqueID>8109361</NlmUniqueID>
            <ISSNLinking>0250-8095</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>5E8K9I0O4U</RegistryNumber>
                <NameOfSubstance UI="D002939">Ciprofloxacin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D058186">Acute Kidney Injury</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001991">Bronchitis</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002939">Ciprofloxacin</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009395">Nephritis, Interstitial</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <NumberOfReferences>19</NumberOfReferences>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1992</Year>
                <Month>1</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1992</Year>
                <Month>1</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1992</Year>
                <Month>1</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">1481877</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">12912971</PMID>
        <DateCreated>
            <Year>2003</Year>
            <Month>08</Month>
            <Day>12</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2004</Year>
            <Month>06</Month>
            <Day>10</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>07</Month>
            <Day>28</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1078-0432</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>9</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2003</Year>
                        <Month>Aug</Month>
                        <Day>1</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Clinical cancer research : an official journal of the American Association for Cancer Research</Title>
                <ISOAbbreviation>Clin. Cancer Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Epidermal growth factor receptor blockade potentiates apoptosis mediated by Paclitaxel and leads to prolonged survival in a murine model of oral cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>3183-9</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Because survival for patients with oral cancer has not improved over the past 25 years, new approaches for treatment are needed. Targeted molecular therapy against epidermal growth factor receptor (EGFR) has shown promise as an adjuvant therapy in preliminary studies in several solid tumors, including head and neck cancer. The objective of this study was to determine the efficacy of paclitaxel and PKI166, a novel inhibitor of EGFR, against oral cavity cancer.</AbstractText>
                <AbstractText Label="EXPERIMENTAL DESIGN AND RESULTS" NlmCategory="RESULTS">JMAR human oral cancer cells were pretreated for 1 h with PKI166 and then stimulated with epidermal growth factor. EGFR-specific tyrosine kinase autophosphorylation measured by Western immunoblotting was inhibited by PKI166 in a dose-dependent fashion at all doses tested (0.01-1 micro M). Next, the induction of apoptosis in JMAR cells treated with paclitaxel (0.001 to 0.1 micro M) with or without PKI166 (0, 1, or 2 micro M) was determined using a propidium iodide assay. The addition of 2.0 micro M PKI166 significantly increased tumor cell death, shifting the amount of paclitaxel needed to induce apoptosis in 50% of cells from 0.1 to 0.001 micro M. These in vitro findings were confirmed using an orthotopic model of oral cancer. JMAR oral cancer cells were implanted into the tongues of nude mice. After lingual tumors developed, mice were randomized into four groups (n = 10): (a) oral PKI166 (100 mg/kg); (b) i.p. paclitaxel (200 micro g/wk); (c) PKI166 and paclitaxel; or (d) placebo. Mice treated with PKI166/paclitaxel demonstrated a significant increase in survival (P = 0.028). After necropsy, all tongue tumors were evaluated for apoptosis by the terminal deoxynucleotidyl transferase-mediated nick end labeling assay. A greater apoptotic fraction of tumor cells was found in tumors of mice treated with paclitaxel and PKI166 as compared with the other treatment groups (136.4 versus 37.8; P = 0.016).</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Combination therapy with paclitaxel and PKI166 prolongs survival in an orthotopic preclinical model of tongue cancer by increasing programmed cell death of oral cancer.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Holsinger</LastName>
                    <ForeName>F Christopher</ForeName>
                    <Initials>FC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Head and Neck Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030-4009, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Doan</LastName>
                    <ForeName>Dao D</ForeName>
                    <Initials>DD</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jasser</LastName>
                    <ForeName>Samar A</ForeName>
                    <Initials>SA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Swan</LastName>
                    <ForeName>Eric A</ForeName>
                    <Initials>EA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Greenberg</LastName>
                    <ForeName>Jayson S</ForeName>
                    <Initials>JS</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Schiff</LastName>
                    <ForeName>Bradley A</ForeName>
                    <Initials>BA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bekele</LastName>
                    <ForeName>B Nebiyou</ForeName>
                    <Initials>BN</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Younes</LastName>
                    <ForeName>Maher N</ForeName>
                    <Initials>MN</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bucana</LastName>
                    <ForeName>Corazon D</ForeName>
                    <Initials>CD</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fidler</LastName>
                    <ForeName>Isaiah J</ForeName>
                    <Initials>IJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Myers</LastName>
                    <ForeName>Jeffrey N</ForeName>
                    <Initials>JN</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Clin Cancer Res</MedlineTA>
            <NlmUniqueID>9502500</NlmUniqueID>
            <ISSNLinking>1078-0432</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000972">Antineoplastic Agents, Phytogenic</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D008024">Ligands</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C410026">PKI 166</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011743">Pyrimidines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011758">Pyrroles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>33069-62-4</RegistryNumber>
                <NameOfSubstance UI="D017239">Paclitaxel</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>36015-30-2</RegistryNumber>
                <NameOfSubstance UI="D011419">Propidium</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>42HK56048U</RegistryNumber>
                <NameOfSubstance UI="D014443">Tyrosine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="D011958">Receptor, Epidermal Growth Factor</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000972">Antineoplastic Agents, Phytogenic</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D017209">Apoptosis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015153">Blotting, Western</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016923">Cell Death</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006258">Head and Neck Neoplasms</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020287">In Situ Nick-End Labeling</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008024">Ligands</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008819">Mice, Nude</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008856">Microscopy, Fluorescence</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009062">Mouth Neoplasms</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000401">mortality</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017239">Paclitaxel</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010766">Phosphorylation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011419">Propidium</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011743">Pyrimidines</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011758">Pyrroles</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011958">Receptor, Epidermal Growth Factor</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014059">Tongue</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014062">Tongue Neoplasms</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014443">Tyrosine</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2003</Year>
                <Month>8</Month>
                <Day>13</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2004</Year>
                <Month>6</Month>
                <Day>21</Day>
                <Hour>10</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2003</Year>
                <Month>8</Month>
                <Day>13</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">12912971</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">16136018</PMID>
        <DateCreated>
            <Year>2005</Year>
            <Month>12</Month>
            <Day>16</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2006</Year>
            <Month>01</Month>
            <Day>17</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0172-780X</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>26</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2005</Year>
                        <Month>Aug</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Neuro endocrinology letters</Title>
                <ISOAbbreviation>Neuro Endocrinol. Lett.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Tetanic crisis and antiepileptic drugs. A case report.</ArticleTitle>
            <Pagination>
                <MedlinePgn>317-9</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="OBJECTIVE AND METHODS" NlmCategory="OBJECTIVE">We presented a rare case of tetanic crisis in a 23-year old mentally retarded woman with epilepsy after treatment by oxcarbazepine, the new anticonvulsant agent. We reviewed laboratory, radiographic and medical examinations and recommend a proper treatment in such cases.</AbstractText>
                <AbstractText Label="RESULTS AND CONCLUSION" NlmCategory="CONCLUSIONS">The laboratory tests revealed only severe hypocalcemia. We described the potential role of oxcarbazepine in the induction of activity of cytochrome P 450 system of hepar and increases of less active metabolism of vitamin D. Supplementation of vitamin D and calcium in patients taking antiepileptic drugs is in the same case crucial.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Zdrojewicz</LastName>
                    <ForeName>Zygmunt</ForeName>
                    <Initials>Z</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Endocrinology &amp; Diabetology, Wroclaw Medical University, Wroclaw, Poland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dubiński</LastName>
                    <ForeName>Andrzej</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jonek</LastName>
                    <ForeName>Aneta</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tomanek</LastName>
                    <ForeName>Natalia</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Krajewski</LastName>
                    <ForeName>Włodzimierz</ForeName>
                    <Initials>W</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Sweden</Country>
            <MedlineTA>Neuro Endocrinol Lett</MedlineTA>
            <NlmUniqueID>8008373</NlmUniqueID>
            <ISSNLinking>0172-780X</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014815">Vitamins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>1406-16-2</RegistryNumber>
                <NameOfSubstance UI="D014807">Vitamin D</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>33CM23913M</RegistryNumber>
                <NameOfSubstance UI="D002220">Carbamazepine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>SY7Q814VUP</RegistryNumber>
                <NameOfSubstance UI="D002118">Calcium</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>VZI5B1W380</RegistryNumber>
                <NameOfSubstance UI="C036006">oxcarbazepine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000927">Anticonvulsants</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002118">Calcium</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002220">Carbamazepine</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000031">analogs &amp; derivatives</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004830">Epilepsy, Tonic-Clonic</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006996">Hypocalcemia</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008607">Intellectual Disability</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013746">Tetany</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014807">Vitamin D</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014815">Vitamins</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2005</Year>
                <Month>3</Month>
                <Day>03</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2005</Year>
                <Month>4</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2005</Year>
                <Month>9</Month>
                <Day>2</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2006</Year>
                <Month>1</Month>
                <Day>18</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2005</Year>
                <Month>9</Month>
                <Day>2</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">NEL260405C03</ArticleId>
            <ArticleId IdType="pubmed">16136018</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">12633131</PMID>
        <DateCreated>
            <Year>2003</Year>
            <Month>03</Month>
            <Day>13</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2003</Year>
            <Month>03</Month>
            <Day>26</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0160-6689</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>64</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>2003</Year>
                        <Month>Feb</Month>
                    </PubDate>
                </JournalIssue>
                <Title>The Journal of clinical psychiatry</Title>
                <ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation>
            </Journal>
            <ArticleTitle>A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder.</ArticleTitle>
            <Pagination>
                <MedlinePgn>208-14</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The monoamine oxidase (MAO) inhibitor selegiline has demonstrated antidepressant efficacy superior to placebo. A selegiline transdermal system (STS) has been developed with unique pharmacokinetic and pharmacodynamic properties that allow inhibition of central nervous system MAO-A and MAO-B enzymes while substantially avoiding inhibition of intestinal and liver MAO-A enzyme. This novel transdermal system provides targeted MAO inhibition without clinically significant increases in sensitivity to dietary tyramine. We investigated the safety and efficacy of STS in patients with major depressive disorder.</AbstractText>
                <AbstractText Label="METHOD" NlmCategory="METHODS">365 outpatients 18 to 65 years old with a DSM-IV diagnosis of major depressive disorder were enrolled at 16 sites. A 17-item Hamilton Rating Scale for Depression (HAM-D-17) score of &gt; or = 20 was required for entry. Patients were randomly assigned to receive either STS, 20 mg/20 cm(2), daily or placebo patch for up to 8 weeks. A tyramine-restricted diet was neither required nor advised. Efficacy, safety, and vital sign measures were obtained regularly.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">289 patients were randomly assigned to treatment and received at least 1 on-therapy evaluation (STS, N = 145; placebo, N = 144). Although the effect size was modest, at endpoint, STS was statistically superior to placebo on the MADRS (p =.001) and HAM-D-28 (p =.039) ratings and showed a nonsignificant superiority on the HAM-D-17 (p =.069) and Clinical Global Impressions-Severity ratings (p &lt;.055). Side effect profiles were similar for STS and placebo with the exception of application-site reaction, which was observed in 31.5% of STS patients and 15.1% of placebo-treated patients (p =.001). No significant differences were observed in blood pressure measures between treatment groups.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Results from this double-blind, placebo-controlled clinical trial demonstrate that STS may have a modest, but statistically significant, antidepressant benefit compared with placebo and a similar safety profile compared with placebo in the absence of a tyramine-restricted diet.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Amsterdam</LastName>
                    <ForeName>Jay D</ForeName>
                    <Initials>JD</Initials>
                    <AffiliationInfo>
                        <Affiliation>Depression Research Unit, Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, USA. jamsterd@mail.med.upenn.edu</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016430">Clinical Trial</PublicationType>
                <PublicationType UI="D003160">Comparative Study</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016448">Multicenter Study</PublicationType>
                <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Clin Psychiatry</MedlineTA>
            <NlmUniqueID>7801243</NlmUniqueID>
            <ISSNLinking>0160-6689</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D008996">Monoamine Oxidase Inhibitors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D010919">Placebos</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>14611-51-9</RegistryNumber>
                <NameOfSubstance UI="D012642">Selegiline</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>X8ZC7V0OX3</RegistryNumber>
                <NameOfSubstance UI="D014439">Tyramine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000279">Administration, Cutaneous</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000553">Ambulatory Care</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003866">Depressive Disorder</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004032">Diet</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004311">Double-Blind Method</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006973">Hypertension</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000517">prevention &amp; control</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008996">Monoamine Oxidase Inhibitors</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010919">Placebos</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011569">Psychiatric Status Rating Scales</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012642">Selegiline</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014439">Tyramine</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2003</Year>
                <Month>3</Month>
                <Day>14</Day>
                <Hour>4</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2003</Year>
                <Month>3</Month>
                <Day>27</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2003</Year>
                <Month>3</Month>
                <Day>14</Day>
                <Hour>4</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">12633131</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">17047157</PMID>
        <DateCreated>
            <Year>2007</Year>
            <Month>01</Month>
            <Day>24</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2007</Year>
            <Month>03</Month>
            <Day>06</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>09</Month>
            <Day>08</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">0006-4971</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>109</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2007</Year>
                        <Month>Feb</Month>
                        <Day>1</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Blood</Title>
                <ISOAbbreviation>Blood</ISOAbbreviation>
            </Journal>
            <ArticleTitle>A soluble form of the Mer receptor tyrosine kinase inhibits macrophage clearance of apoptotic cells and platelet aggregation.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1026-33</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Membrane-bound receptors generate soluble ligand-binding domains either by proteolytic cleavage of the extracellular domain or alternative mRNA splicing yielding a secreted protein. Mertk (Mer) is in a receptor tyrosine kinase family with Axl and Tyro-3, and all 3 receptors share the Gas6 ligand. Mer regulates macrophage activation, promotes apoptotic cell engulfment, and supports platelet aggregation and clot stability in vivo. We have found that the membrane-bound Mer protein is cleaved in the extracellular domain via a metalloproteinase. The cleavage results in the production of a soluble Mer protein released in a constitutive manner from cultured cells. Significant amounts of the soluble Mer protein were also detected in human plasma, suggesting its physiologic relevance. Cleavage of Mer was enhanced by treatment with LPS and PMA and was specifically inhibited by a tumor necrosis factor alpha-converting enzyme metalloproteinase inhibitor. As a decoy receptor for Gas6, soluble Mer prevented Gas6-mediated stimulation of membrane-bound Mer. The inhibition of Gas6 activity by soluble Mer led to defective macrophage-mediated engulfment of apoptotic cells. Furthermore, soluble Mer decreased platelet aggregation in vitro and prevented fatal collagen/epinephrine-induced thromboembolism in mice, suggesting a potential therapeutic use for soluble Mer in the treatment of clotting disorders.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Sather</LastName>
                    <ForeName>Susan</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pediatrics, University of Colorado at Denver, and Health Sciences Center, Aurora, CO 80045, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kenyon</LastName>
                    <ForeName>Karla D</ForeName>
                    <Initials>KD</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lefkowitz</LastName>
                    <ForeName>Jerry B</ForeName>
                    <Initials>JB</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liang</LastName>
                    <ForeName>Xiayuan</ForeName>
                    <Initials>X</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Varnum</LastName>
                    <ForeName>Brian C</ForeName>
                    <Initials>BC</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Henson</LastName>
                    <ForeName>Peter M</ForeName>
                    <Initials>PM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Graham</LastName>
                    <ForeName>Douglas K</ForeName>
                    <Initials>DK</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>GM061031</GrantID>
                    <Acronym>GM</Acronym>
                    <Agency>NIGMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2006</Year>
                <Month>10</Month>
                <Day>17</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Blood</MedlineTA>
            <NlmUniqueID>7603509</NlmUniqueID>
            <ISSNLinking>0006-4971</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D036341">Intercellular Signaling Peptides and Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011518">Proto-Oncogene Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C082281">growth arrest-specific protein 6</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.1.10.1</RegistryNumber>
                <NameOfSubstance UI="C490767">Mertk protein, mouse</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="D020794">Receptor Protein-Tyrosine Kinases</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.4.-</RegistryNumber>
                <NameOfSubstance UI="D045726">Metalloproteases</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 1997 Nov 21;272(47):29411-4</RefSource>
                <PMID Version="1">9367994</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Oncogene. 1997 May 1;14(17):2033-9</RefSource>
                <PMID Version="1">9160883</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Cell Biol. 1999 Feb;19(2):1171-81</RefSource>
                <PMID Version="1">9891051</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Immunol. 1999 Mar 15;162(6):3498-503</RefSource>
                <PMID Version="1">10092806</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Rev Mol Cell Biol. 2005 Jan;6(1):32-43</RefSource>
                <PMID Version="1">15688065</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Invest. 2005 Feb;115(2):237-46</RefSource>
                <PMID Version="1">15650770</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Cell Biol. 2005 Nov;25(21):9324-39</RefSource>
                <PMID Version="1">16227584</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Cancer Res. 2006 May 1;12(9):2662-9</RefSource>
                <PMID Version="1">16675557</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Oncogene. 2006 Oct 5;25(45):6092-100</RefSource>
                <PMID Version="1">16652142</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Cell Proteomics. 2002 Jan;1(1):30-6</RefSource>
                <PMID Version="1">12096138</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 1999 Nov 9;96(23):13264-9</RefSource>
                <PMID Version="1">10557309</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Hum Mol Genet. 2000 Mar 1;9(4):645-51</RefSource>
                <PMID Version="1">10699188</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2000 Nov;26(3):270-1</RefSource>
                <PMID Version="1">11062461</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Immunol. 2001 Feb 1;166(3):1583-9</RefSource>
                <PMID Version="1">11160199</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Med. 2001 Feb;7(2):215-21</RefSource>
                <PMID Version="1">11175853</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 2001 May 10;411(6834):207-11</RefSource>
                <PMID Version="1">11346799</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Endocrinol Metab. 2001 Jul;86(7):3097-107</RefSource>
                <PMID Version="1">11443173</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 2002 Jul 5;277(27):24057-66</RefSource>
                <PMID Version="1">11929866</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Exp Med. 2002 Jul 1;196(1):135-40</RefSource>
                <PMID Version="1">12093878</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Res. 2002 Aug 1;62(15):4398-405</RefSource>
                <PMID Version="1">12154046</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Anticancer Res. 2002 Mar-Apr;22(2B):1071-8</RefSource>
                <PMID Version="1">12168903</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Curr Opin Immunol. 2003 Feb;15(1):31-6</RefSource>
                <PMID Version="1">12495730</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 2002 Dec 27;277(52):50510-9</RefSource>
                <PMID Version="1">12403792</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Immunol. 2003 Dec 15;171(12):6814-9</RefSource>
                <PMID Version="1">14662887</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochem J. 2004 Mar 1;378(Pt 2):383-9</RefSource>
                <PMID Version="1">14594449</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Leukoc Biol. 2004 May;75(5):731-7</RefSource>
                <PMID Version="1">14726496</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Arterioscler Thromb Vasc Biol. 2004 Jun;24(6):1118-23</RefSource>
                <PMID Version="1">15130911</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 1986 Sep;83(18):6716-20</RefSource>
                <PMID Version="1">2944113</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Cell Biol. 1991 Oct;11(10):5016-31</RefSource>
                <PMID Version="1">1656220</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Exp Med. 1992 Feb 1;175(2):323-9</RefSource>
                <PMID Version="1">1310100</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Virol. 1992 Oct;66(10):5975-87</RefSource>
                <PMID Version="1">1527848</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 1994 Jan 21;269(3):1839-44</RefSource>
                <PMID Version="1">7507487</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Oncogene. 1994 Mar;9(3):699-705</RefSource>
                <PMID Version="1">8108112</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Immunol. 1994 May 15;152(10):4958-68</RefSource>
                <PMID Version="1">8176214</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochem J. 1994 Jun 1;300 ( Pt 2):281-90</RefSource>
                <PMID Version="1">8002928</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 1994 Jul 21;370(6486):218-20</RefSource>
                <PMID Version="1">8028669</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Oncogene. 1994 Sep;9(9):2567-78</RefSource>
                <PMID Version="1">8058320</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cell Growth Differ. 1994 Jun;5(6):647-57</RefSource>
                <PMID Version="1">8086340</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 1995 Jan 13;270(2):551-7</RefSource>
                <PMID Version="1">7822279</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cell. 1995 Feb 24;80(4):661-70</RefSource>
                <PMID Version="1">7867073</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Oncogene. 1995 Jun 15;10(12):2349-59</RefSource>
                <PMID Version="1">7784083</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Exp Med. 1995 Aug 1;182(2):549-57</RefSource>
                <PMID Version="1">7543142</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Cell Biol. 1995 Dec;15(12):6582-92</RefSource>
                <PMID Version="1">8524223</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Blood. 1996 Feb 1;87(3):847-57</RefSource>
                <PMID Version="1">8562952</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 1996 Apr 19;271(16):9785-9</RefSource>
                <PMID Version="1">8621659</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochemistry. 1996 Jun 25;35(25):8226-33</RefSource>
                <PMID Version="1">8679577</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Cell Physiol. 1996 Sep;168(3):737-44</RefSource>
                <PMID Version="1">8816929</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 1996 Nov 22;271(47):30022-7</RefSource>
                <PMID Version="1">8939948</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>FEBS Lett. 1997 Jan 20;401(2-3):235-8</RefSource>
                <PMID Version="1">9013894</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochem J. 1997 Jan 15;321 ( Pt 2):265-79</RefSource>
                <PMID Version="1">9020855</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 1997 Feb 20;385(6618):729-33</RefSource>
                <PMID Version="1">9034190</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Leukoc Biol. 1998 Aug;64(2):135-46</RefSource>
                <PMID Version="1">9715251</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D017209">Apoptosis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D036341">Intercellular Signaling Peptides and Proteins</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008262">Macrophage Activation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008264">Macrophages</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D045726">Metalloproteases</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D010587">Phagocytosis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D010974">Platelet Aggregation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011518">Proto-Oncogene Proteins</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020794">Receptor Protein-Tyrosine Kinases</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012995">Solubility</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013923">Thromboembolism</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000517">prevention &amp; control</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">PMC1785151</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2006</Year>
                <Month>10</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2006</Year>
                <Month>10</Month>
                <Day>19</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2007</Year>
                <Month>3</Month>
                <Day>7</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2006</Year>
                <Month>10</Month>
                <Day>19</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">blood-2006-05-021634</ArticleId>
            <ArticleId IdType="doi">10.1182/blood-2006-05-021634</ArticleId>
            <ArticleId IdType="pubmed">17047157</ArticleId>
            <ArticleId IdType="pmc">PMC1785151</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">8902249</PMID>
        <DateCreated>
            <Year>1997</Year>
            <Month>03</Month>
            <Day>20</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1997</Year>
            <Month>03</Month>
            <Day>20</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0333-1024</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>16</Volume>
                    <Issue>6</Issue>
                    <PubDate>
                        <Year>1996</Year>
                        <Month>Oct</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Cephalalgia : an international journal of headache</Title>
                <ISOAbbreviation>Cephalalgia</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Headache induced by a nitric oxide donor (nitroglycerin) responds to sumatriptan. A human model for development of migraine drugs.</ArticleTitle>
            <Pagination>
                <MedlinePgn>412-8</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Experimental &quot;vascular&quot; headache in humans may be used in characterizing new migraine drugs. The effects of sumatriptan on nitroglycerin-(NTG)-induced headache and arterial responses were therefore studied. Following a double-blind randomized crossover design, 10 healthy volunteers received sumatriptan 6 mg s.c. or placebo succeeded by 20 min NTG (0.12 microgram/kg/min) infusion. Headache was rated on a 10 points scale. Temporal and radial artery diameters and velocity in the middle cerebral artery (MCA) were measured with ultrasound. Sumatriptan reduced the NTG-induced headache, median score 1.5 versus 4 after placebo (p &lt; 0.01) and decreased temporal and radial artery diameters 75 +/- 3 and 86 +/- 3% of baseline respectively (p &lt; 0.05). Blood velocity in the MCA was unaffected. The NTG model may prove to be a valuable tool in the development of future migraine drugs. The results suggest that NTG headache in non-migraineurs may share mechanisms with migraine headache.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Iversen</LastName>
                    <ForeName>H K</ForeName>
                    <Initials>HK</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Neurology, Glostrup Hospital, University of Copenhagen, Denmark.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Olesen</LastName>
                    <ForeName>J</ForeName>
                    <Initials>J</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016430">Clinical Trial</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>NORWAY</Country>
            <MedlineTA>Cephalalgia</MedlineTA>
            <NlmUniqueID>8200710</NlmUniqueID>
            <ISSNLinking>0333-1024</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014662">Vasoconstrictor Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014665">Vasodilator Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>31C4KY9ESH</RegistryNumber>
                <NameOfSubstance UI="D009569">Nitric Oxide</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>8R78F6L9VO</RegistryNumber>
                <NameOfSubstance UI="D018170">Sumatriptan</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.14.13.39</RegistryNumber>
                <NameOfSubstance UI="D019001">Nitric Oxide Synthase</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>G59M7S0WS3</RegistryNumber>
                <NameOfSubstance UI="D005996">Nitroglycerin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>Cephalalgia. 1996 Oct;16(6):405</RefSource>
                <PMID Version="1">8902246</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001783">Blood Flow Velocity</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001921">Brain</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000098">blood supply</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018592">Cross-Over Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004311">Double-Blind Method</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006261">Headache</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009569">Nitric Oxide</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D019001">Nitric Oxide Synthase</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005996">Nitroglycerin</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018170">Sumatriptan</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014655">Vascular Resistance</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014662">Vasoconstrictor Agents</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014665">Vasodilator Agents</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1996</Year>
                <Month>10</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1996</Year>
                <Month>10</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1996</Year>
                <Month>10</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">8902249</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">17351913</PMID>
        <DateCreated>
            <Year>2007</Year>
            <Month>10</Month>
            <Day>30</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2007</Year>
            <Month>12</Month>
            <Day>13</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0260-437X</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>27</Volume>
                    <Issue>6</Issue>
                    <PubDate>
                        <MedlineDate>2007 Nov-Dec</MedlineDate>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of applied toxicology : JAT</Title>
                <ISOAbbreviation>J Appl Toxicol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Curcumin reduces indomethacin-induced damage in the rat small intestine.</ArticleTitle>
            <Pagination>
                <MedlinePgn>551-60</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used in clinical medicine. Their utility is, however, often limited by the adverse effects they produce in the gastrointestinal tract. Oxidative stress has been shown to occur in the small intestine in response to the oral administration of indomethacin, an NSAID commonly used in toxicity studies. In view of this, the effect of curcumin, an agent with anti-oxidant properties, was evaluated on indomethacin-induced small intestinal damage in a rat model. Rats were pretreated with various doses of curcumin (20 mg kg(-1), 40 mg kg(-1) and 80 mg kg(-1)) before administering indomethacin at 20 mg kg(-1). Various parameters of oxidative stress and the extent of small intestinal damage produced by indomethacin, with and without pretreatment with curcumin, were measured. Macroscopic ulceration was found to occur in the small intestine in response to indomethacin. The viability of enterocytes from indomethacin-treated animals was significantly lower than those from control animals. Drug-induced oxidative stress was also evident as seen by increases in the levels of malondialdehyde and protein carbonyl and in activities of pro-oxidant enzymes such as myeloperoxidase and xanthine oxidase in indomethacin-treated rats. Concomitant decreases were seen in the activities of the antioxidant enzymes catalase and glutathione peroxidase in these animals. Pretreatment with curcumin was found to ameliorate these drug-induced changes. Thus, curcumin appears to hold promise as an agent that can potentially reduce NSAID-induced small intestinal damage.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Sivalingam</LastName>
                    <ForeName>Nageswaran</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biochemistry, Christian Medical College, Vellore-632002, Tamil Nadu, India.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hanumantharaya</LastName>
                    <ForeName>Raghunath</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Faith</LastName>
                    <ForeName>Minnie</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Basivireddy</LastName>
                    <ForeName>Jayasree</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Balasubramanian</LastName>
                    <ForeName>K A</ForeName>
                    <Initials>KA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jacob</LastName>
                    <ForeName>Molly</ForeName>
                    <Initials>M</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>J Appl Toxicol</MedlineTA>
            <NlmUniqueID>8109495</NlmUniqueID>
            <ISSNLinking>0260-437X</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000975">Antioxidants</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>4Y8F71G49Q</RegistryNumber>
                <NameOfSubstance UI="D008315">Malondialdehyde</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.11.1.6</RegistryNumber>
                <NameOfSubstance UI="D002374">Catalase</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.11.1.7</RegistryNumber>
                <NameOfSubstance UI="D009195">Peroxidase</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.11.1.9</RegistryNumber>
                <NameOfSubstance UI="D005979">Glutathione Peroxidase</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.17.3.2</RegistryNumber>
                <NameOfSubstance UI="D014969">Xanthine Oxidase</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.4.22.-</RegistryNumber>
                <NameOfSubstance UI="D020169">Caspases</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>IT942ZTH98</RegistryNumber>
                <NameOfSubstance UI="D003474">Curcumin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>XXE1CET956</RegistryNumber>
                <NameOfSubstance UI="D007213">Indomethacin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000975">Antioxidants</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020169">Caspases</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002374">Catalase</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002470">Cell Survival</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003474">Curcumin</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004195">Disease Models, Animal</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004381">Duodenal Ulcer</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000517">prevention &amp; control</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020895">Enterocytes</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005979">Glutathione Peroxidase</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007213">Indomethacin</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007421">Intestine, Small</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000201">enzymology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008315">Malondialdehyde</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018384">Oxidative Stress</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009195">Peroxidase</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D050050">Protein Carbonylation</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017208">Rats, Wistar</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014969">Xanthine Oxidase</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2007</Year>
                <Month>3</Month>
                <Day>14</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2007</Year>
                <Month>12</Month>
                <Day>14</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2007</Year>
                <Month>3</Month>
                <Day>14</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jat.1235</ArticleId>
            <ArticleId IdType="pubmed">17351913</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">15749204</PMID>
        <DateCreated>
            <Year>2005</Year>
            <Month>03</Month>
            <Day>07</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2005</Year>
            <Month>06</Month>
            <Day>16</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0167-5273</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>99</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>2005</Year>
                        <Month>Mar</Month>
                        <Day>18</Day>
                    </PubDate>
                </JournalIssue>
                <Title>International journal of cardiology</Title>
                <ISOAbbreviation>Int. J. Cardiol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Late anthracyclines cardiotoxicity associated with infection by Mycoplasma pneumoniae. A case report.</ArticleTitle>
            <Pagination>
                <MedlinePgn>351-3</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>We report the case of a 15-year-old male developing progressive myocardiopathy secondary to late anthracycline cardiotoxicity. At 2 years of age, the patient received chemotherapy with anthracyclines (adriamycin) at an accumulated dose of 510 mg/m2 due to the presence of non-Hodgkin lymphoma which subsided completely and he has been asymptomatic since then. A number of recurrent respiratory infections occurred as triggering factors of the condition, and the laboratory tests evidenced positive serology for Mycoplasma pneumoniae suggesting a recent contact.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Valencia</LastName>
                    <ForeName>José</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Martínez</LastName>
                    <ForeName>Juan Gabriel</ForeName>
                    <Initials>JG</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sogorb</LastName>
                    <ForeName>Francisco</ForeName>
                    <Initials>F</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Niveiro</LastName>
                    <ForeName>María</ForeName>
                    <Initials>M</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016422">Letter</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Ireland</Country>
            <MedlineTA>Int J Cardiol</MedlineTA>
            <NlmUniqueID>8200291</NlmUniqueID>
            <ISSNLinking>0167-5273</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000903">Antibiotics, Antineoplastic</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000907">Antibodies, Bacterial</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>80168379AG</RegistryNumber>
                <NameOfSubstance UI="D004317">Doxorubicin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000903">Antibiotics, Antineoplastic</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000907">Antibodies, Bacterial</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009202">Cardiomyopathies</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004317">Doxorubicin</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008228">Lymphoma, Non-Hodgkin</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D009177">Mycoplasma pneumoniae</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011019">Pneumonia, Mycoplasma</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000382">microbiology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2003</Year>
                <Month>9</Month>
                <Day>30</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2003</Year>
                <Month>11</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2005</Year>
                <Month>3</Month>
                <Day>8</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2005</Year>
                <Month>6</Month>
                <Day>17</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2005</Year>
                <Month>3</Month>
                <Day>8</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0167527304001664</ArticleId>
            <ArticleId IdType="doi">10.1016/j.ijcard.2003.11.047</ArticleId>
            <ArticleId IdType="pubmed">15749204</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">15749201</PMID>
        <DateCreated>
            <Year>2005</Year>
            <Month>03</Month>
            <Day>07</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2005</Year>
            <Month>06</Month>
            <Day>16</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0167-5273</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>99</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>2005</Year>
                        <Month>Mar</Month>
                        <Day>18</Day>
                    </PubDate>
                </JournalIssue>
                <Title>International journal of cardiology</Title>
                <ISOAbbreviation>Int. J. Cardiol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>A novel mutation in FKBP12.6 binding region of the human cardiac ryanodine receptor gene (R2401H) in a Japanese patient with catecholaminergic polymorphic ventricular tachycardia.</ArticleTitle>
            <Pagination>
                <MedlinePgn>343-5</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an autosomal dominant inherited disorder characterized by adrenergic induced polymorphic ventricular tachycardias and associated with sudden cardiac death. The human cardiac ryanodine receptor gene (RyR2) was linked to CPVT. A 20-year-old male was referred to our hospital because of recurrent syncope after physical and emotional stress. Routine cardiac examinations including catheterization revealed no structural abnormality. Exercise on treadmill induced premature ventricular contraction in bigeminy and bidirectional ventricular tachycardia was induced during isoproterenol infusion. Beta-blocking drug was effective in suppressing the arrhythmias. We performed genetic screening by PCR-SSCP method followed by DNA sequencing, and a novel missense mutation R2401H in RyR2 located in FKBP12.6 binding region was identified. This mutation was not detected in 190 healthy controls. Since FKBP12.6 plays a critical role in Ca channel gating, the R2401H mutation can be expected to alter Ca-induced Ca release and E-C coupling resulting in CPVT. This is the first report of RyR2 mutation in CPVT patient from Asia including Japan.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Aizawa</LastName>
                    <ForeName>Yoshiyasu</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ueda</LastName>
                    <ForeName>Kazuo</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Komura</LastName>
                    <ForeName>Satoru</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Washizuka</LastName>
                    <ForeName>Takashi</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chinushi</LastName>
                    <ForeName>Masaomi</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Inagaki</LastName>
                    <ForeName>Natsuko</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Matsumoto</LastName>
                    <ForeName>Yuji</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hayashi</LastName>
                    <ForeName>Takeharu</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Takahashi</LastName>
                    <ForeName>Megumi</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nakano</LastName>
                    <ForeName>Noritsugu</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yasunami</LastName>
                    <ForeName>Michio</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kimura</LastName>
                    <ForeName>Akinori</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hiraoka</LastName>
                    <ForeName>Masayasu</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Aizawa</LastName>
                    <ForeName>Yoshifusa</ForeName>
                    <Initials>Y</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016422">Letter</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Ireland</Country>
            <MedlineTA>Int J Cardiol</MedlineTA>
            <NlmUniqueID>8200291</NlmUniqueID>
            <ISSNLinking>0167-5273</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000318">Adrenergic beta-Agonists</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D019837">Ryanodine Receptor Calcium Release Channel</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 5.2.1.-</RegistryNumber>
                <NameOfSubstance UI="D022021">Tacrolimus Binding Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 5.2.1.-</RegistryNumber>
                <NameOfSubstance UI="C403484">tacrolimus binding protein 1B</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>L628TT009W</RegistryNumber>
                <NameOfSubstance UI="D007545">Isoproterenol</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000318">Adrenergic beta-Agonists</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000176">diagnostic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005080">Exercise Test</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007545">Isoproterenol</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000176">diagnostic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D020125">Mutation, Missense</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016133">Polymerase Chain Reaction</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018807">Polymorphism, Single-Stranded Conformational</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D019837">Ryanodine Receptor Calcium Release Channel</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017180">Tachycardia, Ventricular</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D022021">Tacrolimus Binding Proteins</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2003</Year>
                <Month>9</Month>
                <Day>5</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2003</Year>
                <Month>11</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2005</Year>
                <Month>3</Month>
                <Day>8</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2005</Year>
                <Month>6</Month>
                <Day>17</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2005</Year>
                <Month>3</Month>
                <Day>8</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0167527304001482</ArticleId>
            <ArticleId IdType="doi">10.1016/j.ijcard.2003.11.050</ArticleId>
            <ArticleId IdType="pubmed">15749201</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">11321437</PMID>
        <DateCreated>
            <Year>2001</Year>
            <Month>04</Month>
            <Day>25</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2001</Year>
            <Month>09</Month>
            <Day>13</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1386-0291</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>23</Volume>
                    <Issue>2-4</Issue>
                    <PubDate>
                        <Year>2000</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Clinical hemorheology and microcirculation</Title>
                <ISOAbbreviation>Clin. Hemorheol. Microcirc.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Phytochemical analysis and hemodynamic actions of Artemisia vulgaris L.</ArticleTitle>
            <Pagination>
                <MedlinePgn>167-75</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Artemisia vulgaris L. is widely used in the Philippines for its anti-inflammatory properties. The plant was cultivated and mature leaves were collected and washed. The dried leaves were extracted with both distilled water and chloroform. NMR data were obtained using a Varian Unity 500 MHz spectrophotometer. High and low-resolution mass spectra were obtained on a Finnigan MAT 96 high resolution gas chromatograph/mass spectrophotometer with a MAT ICIS operating system. The leaves yielded 2 sesquiterpene lactones and a novel aromatic compound. Two partition fractions from the aqueous extracts and four partition fractions from the chloroform extracts were tested on male Sprague-Dawley rats using both the in situ mesenteric circulation and the isolated perfused mesentery. In the isolated perfused rat mesentery, administration of 10% w/v solutions of water extract fractions FGN 63-1 and FGN 63-2 of A. vulgaris were highly effective in reversing the hypertensive action induced by norepinephrine, but they did not change the regional mesenteric pressures when given at baseline. In the intact rat, injection of 10 mg/ml of FGN 63-1 and chloroform extract FGN 64-2 did not significantly alter baseline blood pressures, but were able to reverse the increase in mean systolic and diastolic pressures induced by norepinephrine. The same fractions did not exert any significant effect on heart rate in either the normotensive or hypertensive states. The present data suggest that aqueous and chloroform extracts from leaves of A. vulgaris have anti-hypertensive actions but have no significant effects on cardiovascular hemodynamics under basal conditions.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Tigno</LastName>
                    <ForeName>X T</ForeName>
                    <Initials>XT</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Physiology, College of Medicine, University of the Philippines Manila, Ermita. xtigno@i-next.net</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>de Guzman</LastName>
                    <ForeName>F</ForeName>
                    <Initials>F</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Flora</LastName>
                    <ForeName>A M</ForeName>
                    <Initials>AM</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D003160">Comparative Study</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>Clin Hemorheol Microcirc</MedlineTA>
            <NlmUniqueID>9709206</NlmUniqueID>
            <ISSNLinking>1386-0291</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C434252">1,2,3,4-diepoxy-11(13)-eudesmen-12,8-olide</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000959">Antihypertensive Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D004149">Dioxoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D004852">Epoxy Compounds</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C434253">FGN 53-2</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007783">Lactones</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D010936">Plant Extracts</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D012717">Sesquiterpenes</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D045787">Sesquiterpenes, Eudesmane</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C117320">yomogin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>059QF0KO0R</RegistryNumber>
                <NameOfSubstance UI="D014867">Water</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>3K9958V90M</RegistryNumber>
                <NameOfSubstance UI="D000431">Ethanol</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>7V31YC746X</RegistryNumber>
                <NameOfSubstance UI="D002725">Chloroform</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>X4W3ENH1CV</RegistryNumber>
                <NameOfSubstance UI="D009638">Norepinephrine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000959">Antihypertensive Agents</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000302">isolation &amp; purification</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D019306">Artemisia</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001794">Blood Pressure</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002725">Chloroform</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004149">Dioxoles</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000302">isolation &amp; purification</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004353">Drug Evaluation, Preclinical</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004852">Epoxy Compounds</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000302">isolation &amp; purification</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000431">Ethanol</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008401">Gas Chromatography-Mass Spectrometry</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006339">Heart Rate</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006439">Hemodynamics</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006973">Hypertension</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007783">Lactones</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000302">isolation &amp; purification</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017538">Mesenteric Artery, Superior</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009638">Norepinephrine</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010477">Perfusion</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010936">Plant Extracts</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000302">isolation &amp; purification</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018515">Plant Leaves</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D010946">Plants, Medicinal</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017207">Rats, Sprague-Dawley</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012717">Sesquiterpenes</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000302">isolation &amp; purification</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D045787">Sesquiterpenes, Eudesmane</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013152">Splanchnic Circulation</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014867">Water</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2001</Year>
                <Month>4</Month>
                <Day>26</Day>
                <Hour>10</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2001</Year>
                <Month>9</Month>
                <Day>14</Day>
                <Hour>10</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2001</Year>
                <Month>4</Month>
                <Day>26</Day>
                <Hour>10</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">11321437</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">24091600</PMID>
        <DateCreated>
            <Year>2013</Year>
            <Month>12</Month>
            <Day>06</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2014</Year>
            <Month>02</Month>
            <Day>07</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2015</Year>
            <Month>04</Month>
            <Day>09</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1522-1547</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>305</Volume>
                    <Issue>11</Issue>
                    <PubDate>
                        <Year>2013</Year>
                        <Month>Dec</Month>
                    </PubDate>
                </JournalIssue>
                <Title>American journal of physiology. Gastrointestinal and liver physiology</Title>
                <ISOAbbreviation>Am. J. Physiol. Gastrointest. Liver Physiol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Mechanisms of STAT3 activation in the liver of FXR knockout mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn>G829-37</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1152/ajpgi.00155.2013</ELocationID>
            <Abstract>
                <AbstractText>Farnesoid X receptor (FXR, Nr1h4) is a ligand-activated transcription factor belonging to the nuclear receptor superfamily. FXR is essential in maintaining bile acid (BA) homeostasis, and FXR(-/-) mice develop cholestasis, inflammation, and spontaneous liver tumors. The signal transducer and activator of transcription 3 (STAT3) is well known to regulate liver growth, and STAT3 is feedback inhibited by its target gene, the suppressor of cytokine signaling 3 (SOCS3). Strong activation of STAT3 was detected in FXR(-/-) mouse livers. However, the mechanism of STAT3 activation with FXR deficiency remains elusive. Wild-type (WT) and FXR(-/-) mice were used to detect STAT3 pathway activation in the liver. In vivo BA feeding or deprivation was used to determine the role of BAs in STAT3 activation, and in vitro molecular approaches were used to determine the direct transcriptional regulation of SOCS3 by FXR. STAT3 was activated in FXR(-/-) but not WT mice. BA feeding increased, but deprivation by cholestyramine reduced, serum inflammatory markers and STAT3 activation. Furthermore, the Socs3 gene was determined as a direct FXR target gene. The elevated BAs and inflammation, along with reduced SOCS3, collectively contribute to the activation of the STAT3 signaling pathway in the liver of FXR(-/-) mice. This study suggests that the constitutive activation of STAT3 may be a mechanism of liver carcinogenesis in FXR(-/-) mice.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Guodong</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Dept. of Pharmacology and Toxicology, School of Pharmacy, Rutgers Univ., Piscataway, NJ 08854. guo@eohsi.rutgers.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhu</LastName>
                    <ForeName>Yan</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tawfik</LastName>
                    <ForeName>Ossama</ForeName>
                    <Initials>O</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kong</LastName>
                    <ForeName>Bo</ForeName>
                    <Initials>B</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Williams</LastName>
                    <ForeName>Jessica A</ForeName>
                    <Initials>JA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhan</LastName>
                    <ForeName>Le</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kassel</LastName>
                    <ForeName>Karen M</ForeName>
                    <Initials>KM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Luyendyk</LastName>
                    <ForeName>James P</ForeName>
                    <Initials>JP</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Li</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Guo</LastName>
                    <ForeName>Grace L</ForeName>
                    <Initials>GL</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>DK-080440</GrantID>
                    <Acronym>DK</Acronym>
                    <Agency>NIDDK NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>DK-081343</GrantID>
                    <Acronym>DK</Acronym>
                    <Agency>NIDDK NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>DK-090036</GrantID>
                    <Acronym>DK</Acronym>
                    <Agency>NIDDK NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>P20 RR015563</GrantID>
                    <Acronym>RR</Acronym>
                    <Agency>NCRR NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>P20 RR021940</GrantID>
                    <Acronym>RR</Acronym>
                    <Agency>NCRR NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>P30 ES005022</GrantID>
                    <Acronym>ES</Acronym>
                    <Agency>NIEHS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 DK081343</GrantID>
                    <Acronym>DK</Acronym>
                    <Agency>NIDDK NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 GM104037</GrantID>
                    <Acronym>GM</Acronym>
                    <Agency>NIGMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R56 DK090036</GrantID>
                    <Acronym>DK</Acronym>
                    <Agency>NIDDK NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2013</Year>
                <Month>10</Month>
                <Day>03</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Am J Physiol Gastrointest Liver Physiol</MedlineTA>
            <NlmUniqueID>100901227</NlmUniqueID>
            <ISSNLinking>0193-1857</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D001647">Bile Acids and Salts</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018160">Receptors, Cytoplasmic and Nuclear</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D050796">STAT3 Transcription Factor</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C491411">Socs3 protein, mouse</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C494087">Stat3 protein, mouse</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D050826">Suppressor of Cytokine Signaling Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C094063">farnesoid X-activated receptor</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>11041-12-6</RegistryNumber>
                <NameOfSubstance UI="D002792">Cholestyramine Resin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 2003 Nov 14;278(46):45062-71</RefSource>
                <PMID Version="1">12923173</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Endocrinol. 1995 Jan;9(1):72-85</RefSource>
                <PMID Version="1">7760852</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 1997 Jun 26;387(6636):917-21</RefSource>
                <PMID Version="1">9202125</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Science. 1999 May 21;284(5418):1362-5</RefSource>
                <PMID Version="1">10334992</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Science. 1999 May 21;284(5418):1365-8</RefSource>
                <PMID Version="1">10334993</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Cell. 1999 May;3(5):543-53</RefSource>
                <PMID Version="1">10360171</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Oncogene. 2005 Sep 22;24(42):6406-17</RefSource>
                <PMID Version="1">16007195</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Gastroenterology. 2006 Jul;131(1):179-93</RefSource>
                <PMID Version="1">16831601</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Res. 2007 Feb 1;67(3):863-7</RefSource>
                <PMID Version="1">17283114</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Carcinogenesis. 2007 May;28(5):940-6</RefSource>
                <PMID Version="1">17183066</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Hepatology. 2008 Jan;47(1):105-12</RefSource>
                <PMID Version="1">17935223</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 2008 Jan 11;283(2):708-15</RefSource>
                <PMID Version="1">17993646</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ann Oncol. 2008 Feb;19(2):353-8</RefSource>
                <PMID Version="1">17962206</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Trends Mol Med. 2008 Mar;14(3):109-19</RefSource>
                <PMID Version="1">18261959</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Endocrinol. 2008 Jul;22(7):1622-32</RefSource>
                <PMID Version="1">18436567</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Hepatology. 2008 Nov;48(5):1632-43</RefSource>
                <PMID Version="1">18972444</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochem Biophys Res Commun. 2009 Feb 6;379(2):476-9</RefSource>
                <PMID Version="1">19118524</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Pharmacol Exp Ther. 2009 Feb;328(2):469-77</RefSource>
                <PMID Version="1">18981289</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ann N Y Acad Sci. 2009 Aug;1171:59-76</RefSource>
                <PMID Version="1">19723038</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Rev Cancer. 2009 Nov;9(11):798-809</RefSource>
                <PMID Version="1">19851315</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Toxicol Appl Pharmacol. 2010 Feb 15;243(1):63-7</RefSource>
                <PMID Version="1">19931294</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Cell. 2010 Mar 16;17(3):286-97</RefSource>
                <PMID Version="1">20227042</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Hepatology. 2010 Apr;51(4):1410-9</RefSource>
                <PMID Version="1">20091679</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Endocrinol. 2010 Jul;24(7):1404-12</RefSource>
                <PMID Version="1">20444884</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Hepatol. 2012 Nov;57(5):1004-12</RefSource>
                <PMID Version="1">22728874</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Arch Toxicol. 2013 Feb;87(2):227-47</RefSource>
                <PMID Version="1">23007558</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nucleic Acids Res. 2010 Oct;38(18):6007-17</RefSource>
                <PMID Version="1">20483916</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pharmacol Res. 2011 Apr;63(4):259-65</RefSource>
                <PMID Version="1">21211565</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Biol Sci. 2011;7(5):536-50</RefSource>
                <PMID Version="1">21552420</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Pharmacol Exp Ther. 2011 Jul;338(1):12-21</RefSource>
                <PMID Version="1">21430080</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Toxicol Appl Pharmacol. 2012 Jan 15;258(2):268-74</RefSource>
                <PMID Version="1">22178739</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Cancer Ther. 2012 Feb;11(2):452-63</RefSource>
                <PMID Version="1">22180308</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Gastroenterology. 2012 May;142(5):1206-1217.e7</RefSource>
                <PMID Version="1">22265968</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>PLoS One. 2012;7(4):e35895</RefSource>
                <PMID Version="1">22540009</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Gastroenterology. 2002 May;122(5):1483-92</RefSource>
                <PMID Version="1">11984532</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cell. 2000 Sep 15;102(6):731-44</RefSource>
                <PMID Version="1">11030617</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Hepatology. 2012 Sep;56(3):1034-43</RefSource>
                <PMID Version="1">22467244</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Immunol. 2003 Jun;4(6):540-5</RefSource>
                <PMID Version="1">12754505</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001647">Bile Acids and Salts</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000172">deficiency</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002792">Cholestyramine Resin</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016207">Cytokines</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008099">Liver</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018345">Mice, Knockout</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018160">Receptors, Cytoplasmic and Nuclear</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D050796">STAT3 Transcription Factor</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D050826">Suppressor of Cytokine Signaling Proteins</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014158">Transcription, Genetic</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">PMC3882431</OtherID>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">bile acids</Keyword>
            <Keyword MajorTopicYN="N">cancer</Keyword>
            <Keyword MajorTopicYN="N">farnesoid X receptor</Keyword>
            <Keyword MajorTopicYN="N">signal transducer and activator of transcription 3</Keyword>
            <Keyword MajorTopicYN="N">suppressor of cytokine signaling 3</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2013</Year>
                <Month>10</Month>
                <Day>3</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2013</Year>
                <Month>10</Month>
                <Day>5</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2013</Year>
                <Month>10</Month>
                <Day>5</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>2</Month>
                <Day>8</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">24091600</ArticleId>
            <ArticleId IdType="pii">ajpgi.00155.2013</ArticleId>
            <ArticleId IdType="doi">10.1152/ajpgi.00155.2013</ArticleId>
            <ArticleId IdType="pmc">PMC3882431</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">17517660</PMID>
        <DateCreated>
            <Year>2007</Year>
            <Month>05</Month>
            <Day>23</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2007</Year>
            <Month>08</Month>
            <Day>01</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>09</Month>
            <Day>04</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">0027-8424</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>104</Volume>
                    <Issue>21</Issue>
                    <PubDate>
                        <Year>2007</Year>
                        <Month>May</Month>
                        <Day>22</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Proceedings of the National Academy of Sciences of the United States of America</Title>
                <ISOAbbreviation>Proc. Natl. Acad. Sci. U.S.A.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>NRAS mutation causes a human autoimmune lymphoproliferative syndrome.</ArticleTitle>
            <Pagination>
                <MedlinePgn>8953-8</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>The p21 RAS subfamily of small GTPases, including KRAS, HRAS, and NRAS, regulates cell proliferation, cytoskeletal organization, and other signaling networks, and is the most frequent target of activating mutations in cancer. Activating germline mutations of KRAS and HRAS cause severe developmental abnormalities leading to Noonan, cardio-facial-cutaneous, and Costello syndrome, but activating germline mutations of NRAS have not been reported. Autoimmune lymphoproliferative syndrome (ALPS) is the most common genetic disease of lymphocyte apoptosis and causes autoimmunity as well as excessive lymphocyte accumulation, particularly of CD4(-), CD8(-) alphabeta T cells. Mutations in ALPS typically affect CD95 (Fas/APO-1)-mediated apoptosis, one of the extrinsic death pathways involving TNF receptor superfamily proteins, but certain ALPS individuals have no such mutations. We show here that the salient features of ALPS as well as a predisposition to hematological malignancies can be caused by a heterozygous germline Gly13Asp activating mutation of the NRAS oncogene that does not impair CD95-mediated apoptosis. The increase in active, GTP-bound NRAS augments RAF/MEK/ERK signaling, which markedly decreases the proapoptotic protein BIM and attenuates intrinsic, nonreceptor-mediated mitochondrial apoptosis. Thus, germline activating mutations in NRAS differ from other p21 Ras oncoproteins by causing selective immune abnormalities without general developmental defects. Our observations on the effects of NRAS activation indicate that RAS-inactivating drugs, such as farnesyltransferase inhibitors should be examined in human autoimmune and lymphocyte homeostasis disorders.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Oliveira</LastName>
                    <ForeName>João B</ForeName>
                    <Initials>JB</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Laboratory Medicine, Clinical Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bidère</LastName>
                    <ForeName>Nicolas</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Niemela</LastName>
                    <ForeName>Julie E</ForeName>
                    <Initials>JE</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zheng</LastName>
                    <ForeName>Lixin</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sakai</LastName>
                    <ForeName>Keiko</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nix</LastName>
                    <ForeName>Cynthia P</ForeName>
                    <Initials>CP</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Danner</LastName>
                    <ForeName>Robert L</ForeName>
                    <Initials>RL</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Barb</LastName>
                    <ForeName>Jennifer</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Munson</LastName>
                    <ForeName>Peter J</ForeName>
                    <Initials>PJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Puck</LastName>
                    <ForeName>Jennifer M</ForeName>
                    <Initials>JM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dale</LastName>
                    <ForeName>Janet</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Straus</LastName>
                    <ForeName>Stephen E</ForeName>
                    <Initials>SE</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fleisher</LastName>
                    <ForeName>Thomas A</ForeName>
                    <Initials>TA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lenardo</LastName>
                    <ForeName>Michael J</ForeName>
                    <Initials>MJ</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <DataBankList CompleteYN="Y">
                <DataBank>
                    <DataBankName>GEO</DataBankName>
                    <AccessionNumberList>
                        <AccessionNumber>GSE7345</AccessionNumber>
                    </AccessionNumberList>
                </DataBank>
            </DataBankList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
                <PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2007</Year>
                <Month>05</Month>
                <Day>16</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Proc Natl Acad Sci U S A</MedlineTA>
            <NlmUniqueID>7505876</NlmUniqueID>
            <ISSNLinking>0027-8424</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D051017">Apoptosis Regulatory Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C110430">Bcl-2-like protein 11</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007376">Interleukin-2</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011518">Proto-Oncogene Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D019253">Proto-Oncogene Proteins c-bcl-2</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.11.24</RegistryNumber>
                <NameOfSubstance UI="D048049">Extracellular Signal-Regulated MAP Kinases</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.6.5.2</RegistryNumber>
                <NameOfSubstance UI="D018631">ras Proteins</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Blood. 1990 Mar 1;75(5):1163-9</RefSource>
                <PMID Version="1">2407301</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Annu Rev Biochem. 1987;56:779-827</RefSource>
                <PMID Version="1">3304147</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Invest. 1996 Sep 1;98(5):1107-13</RefSource>
                <PMID Version="1">8787672</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Genes Dev. 1997 Oct 1;11(19):2468-81</RefSource>
                <PMID Version="1">9334313</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cell. 1999 Jul 9;98(1):47-58</RefSource>
                <PMID Version="1">10412980</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Curr Opin Allergy Clin Immunol. 2004 Dec;4(6):497-503</RefSource>
                <PMID Version="1">15640690</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Rev Immunol. 2005 Mar;5(3):189-200</RefSource>
                <PMID Version="1">15719025</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Cell. 2005 Mar;7(3):227-38</RefSource>
                <PMID Version="1">15766661</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Carcinogenesis. 2005 Jul;26(7):1224-32</RefSource>
                <PMID Version="1">15760917</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cell Death Differ. 2005 Aug;12(8):1008-14</RefSource>
                <PMID Version="1">15947788</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2005 Oct;37(10):1038-40</RefSource>
                <PMID Version="1">16170316</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Curr Mol Med. 2005 Nov;5(7):643-52</RefSource>
                <PMID Version="1">16305490</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2006 Mar;38(3):294-6</RefSource>
                <PMID Version="1">16474404</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2006 Mar;38(3):331-6</RefSource>
                <PMID Version="1">16474405</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Science. 2006 Mar 3;311(5765):1287-90</RefSource>
                <PMID Version="1">16439621</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Annu Rev Immunol. 2006;24:321-52</RefSource>
                <PMID Version="1">16551252</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Annu Rev Immunol. 2006;24:771-800</RefSource>
                <PMID Version="1">16551266</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cold Spring Harb Symp Quant Biol. 2005;70:461-7</RefSource>
                <PMID Version="1">16869784</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Curr Biol. 2006 Aug 22;16(16):1666-71</RefSource>
                <PMID Version="1">16920630</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Hum Mol Genet. 2006 Oct 15;15 Spec No 2:R220-6</RefSource>
                <PMID Version="1">16987887</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2007 Jan;39(1):75-9</RefSource>
                <PMID Version="1">17143282</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Science. 1999 Nov 26;286(5445):1735-8</RefSource>
                <PMID Version="1">10576740</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Cell Biol. 2001 Mar;21(5):1444-52</RefSource>
                <PMID Version="1">11238881</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Blood. 2001 Oct 15;98(8):2466-73</RefSource>
                <PMID Version="1">11588044</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Science. 2001 Nov 9;294(5545):1299-304</RefSource>
                <PMID Version="1">11701921</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Methods. 2001 Dec;25(4):402-8</RefSource>
                <PMID Version="1">11846609</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Res. 2003 Apr 1;63(7):1615-22</RefSource>
                <PMID Version="1">12670913</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 2003 May 23;278(21):18811-6</RefSource>
                <PMID Version="1">12646560</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Rev Cancer. 2003 Jun;3(6):459-65</RefSource>
                <PMID Version="1">12778136</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cell. 2004 Jan 23;116(2):205-19</RefSource>
                <PMID Version="1">14744432</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 2004 Mar 5;279(10):8837-47</RefSource>
                <PMID Version="1">14681225</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>N Engl J Med. 2004 Sep 30;351(14):1409-18</RefSource>
                <PMID Version="1">15459302</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Trends Immunol. 2004 Nov;25(11):610-5</RefSource>
                <PMID Version="1">15489190</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 1985 Jun 27-Jul 3;315(6022):726-30</RefSource>
                <PMID Version="1">2989702</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cell. 1995 Jun 16;81(6):935-46</RefSource>
                <PMID Version="1">7540117</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051017">Apoptosis Regulatory Proteins</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001327">Autoimmune Diseases</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002478">Cells, Cultured</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015536">Down-Regulation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D048049">Extracellular Signal-Regulated MAP Kinases</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020869">Gene Expression Profiling</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007376">Interleukin-2</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008232">Lymphoproliferative Disorders</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008565">Membrane Proteins</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009154">Mutation</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011518">Proto-Oncogene Proteins</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D019253">Proto-Oncogene Proteins c-bcl-2</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D034622">RNA Interference</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018631">ras Proteins</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">PMC1885609</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2007</Year>
                <Month>5</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2007</Year>
                <Month>5</Month>
                <Day>23</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2007</Year>
                <Month>8</Month>
                <Day>2</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2007</Year>
                <Month>5</Month>
                <Day>23</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">0702975104</ArticleId>
            <ArticleId IdType="doi">10.1073/pnas.0702975104</ArticleId>
            <ArticleId IdType="pubmed">17517660</ArticleId>
            <ArticleId IdType="pmc">PMC1885609</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">14769840</PMID>
        <DateCreated>
            <Year>2004</Year>
            <Month>02</Month>
            <Day>10</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2004</Year>
            <Month>04</Month>
            <Day>13</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0368-2811</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>33</Volume>
                    <Issue>12</Issue>
                    <PubDate>
                        <Year>2003</Year>
                        <Month>Dec</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Japanese journal of clinical oncology</Title>
                <ISOAbbreviation>Jpn. J. Clin. Oncol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Study of paclitaxel and dose escalation of cisplatin in patients with advanced non-small cell lung cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>626-30</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">We conducted a dose-finding and feasibility study in which we administered a fixed dose 3-h infusion of paclitaxel and an escalating dose of cisplatin in Japanese patients with advanced non-small cell lung cancer.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Chemotherapy consisted of fixed dose (210 mg/m(2)) paclitaxel given over 3 h on day 1 and an escalating dose of cisplatin on day 2, every 3-4 weeks. The dose of cisplatin was 40 mg/m(2) at level 1, 60 mg/m(2) at level 2 and 80 mg/m(2) at level 3.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Between October 1999 and February 2001, 24 patients were enrolled and 58 cycles were administered. The major hematological toxicities were leukopenia and neutropenia. Grade 4 neutropenia developed in 83.3%, 66.7% and 83.3% of patients at the dose levels of 1, 2 and 3, respectively. The major non-hematological toxicities consisted of alanine aminotransferase (ALT) elevation and peripheral neuropathy. Grade 3 ALT elevation was observed in two of the 12 patients at level 3, but both recovered within 3 days. The peripheral neuropathy was sensory-dominant and frequent, and it was almost tolerable. The maximum tolerated dose was not identified even at the highest dose of paclitaxel (210 mg/m(2)) and cisplatin (80 mg/m(2)) administered in the study. The recommended dose was determined to be paclitaxel 210 mg/m(2) on day 1 and cisplatin 80 mg/m(2) on day 2, every 3-4 weeks. Seven partial responses were observed in the 24 patients.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The combination of paclitaxel 210 mg/m(2) and cisplatin 80 mg/m(2) was found to be a well-tolerated active regimen in Japanese patients with advanced non-small cell lung cancer.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Watanabe</LastName>
                    <ForeName>Hirokazu</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Internal Medicine, National Cancer Center Hospital, Tokyo, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yamamoto</LastName>
                    <ForeName>Noboru</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tamura</LastName>
                    <ForeName>Tomohide</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shimoyama</LastName>
                    <ForeName>Tatsu</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hotta</LastName>
                    <ForeName>Katsuyuki</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Inoue</LastName>
                    <ForeName>Akira</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sawada</LastName>
                    <ForeName>Masahiro</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Akiyama</LastName>
                    <ForeName>Yoshiko</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kusaba</LastName>
                    <ForeName>Hitoshi</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nokihara</LastName>
                    <ForeName>Hiroshi</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sekine</LastName>
                    <ForeName>Ikuo</ForeName>
                    <Initials>I</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kunitoh</LastName>
                    <ForeName>Hideo</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ohe</LastName>
                    <ForeName>Yuichiro</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kodama</LastName>
                    <ForeName>Tetsuro</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Saijo</LastName>
                    <ForeName>Nagahiro</ForeName>
                    <Initials>N</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Japan</Country>
            <MedlineTA>Jpn J Clin Oncol</MedlineTA>
            <NlmUniqueID>0313225</NlmUniqueID>
            <ISSNLinking>0368-2811</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>33069-62-4</RegistryNumber>
                <NameOfSubstance UI="D017239">Paclitaxel</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>Q20Q21Q62J</RegistryNumber>
                <NameOfSubstance UI="D002945">Cisplatin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000971">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002289">Carcinoma, Non-Small-Cell Lung</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002945">Cisplatin</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004334">Drug Administration Schedule</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005240">Feasibility Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007970">Leukopenia</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008175">Lung Neoplasms</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020714">Maximum Tolerated Dose</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009503">Neutropenia</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017239">Paclitaxel</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010523">Peripheral Nervous System Diseases</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2004</Year>
                <Month>2</Month>
                <Day>11</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2004</Year>
                <Month>4</Month>
                <Day>14</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2004</Year>
                <Month>2</Month>
                <Day>11</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">14769840</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">22954649</PMID>
        <DateCreated>
            <Year>2013</Year>
            <Month>02</Month>
            <Day>21</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2013</Year>
            <Month>07</Month>
            <Day>29</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2015</Year>
            <Month>02</Month>
            <Day>20</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">2040-2058</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>18</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2013</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Antiviral therapy</Title>
                <ISOAbbreviation>Antivir. Ther. (Lond.)</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Cytolytic nanoparticles attenuate HIV-1 infectivity.</ArticleTitle>
            <Pagination>
                <MedlinePgn>95-103</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.3851/IMP2346</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">We investigated whether cytolytic melittin peptides could inhibit HIV-1 infectivity when carried in a nanoparticle construct that might be used as a topical vaginal virucide. Free melittin and melittin-loaded nanoparticles were prepared and compared for cytotoxicity and their ability to inhibit infectivity by CXCR4 and CCR5 tropic HIV-1 strains.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">TZM-bl reporter cells expressing luciferase under the control of the HIV-1 promoter were incubated with HIV-1 NLHX (CXCR4) or HIV-1 NLYU2 (CCR5) viral strains and different doses of soluble CD4 (positive control) or free melittin to determine infectivity and viability. Melittin-loaded nanoparticles were formulated and different doses tested against VK2 vaginal epithelial cells to determine cell viability. Based on VK2 viability, melittin nanoparticles were tested for prevention of CXCR4 and CCR5 tropic HIV-1 infectivity and viability of TZM-bl reporter cells. Low-speed centrifugation was used to compare the ability of blank non-melittin nanoparticles and melittin nanoparticles to capture CCR5 tropic HIV-1.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">As expected, the soluble CD4 positive control inhibited CXCR4 (50% inhibitory concentration [IC₅₀] 3.7 μg/ml) and CCR5 (IC₅₀ 0.03 μg/ml) tropic HIV-1 infectivity. Free melittin doses &lt;2 μM were not cytotoxic and were highly effective in reducing HIV-1 infectivity for both CXCR4 and CCR5 strains in TZM-bl reporter cells, while VK2 vaginal cell viability was adversely affected at all free melittin doses tested. However, VK2 cell viability was not affected at any dose of melittin-loaded nanoparticles. Melittin nanoparticles safely and significantly decreased CXCR4 (IC₅₀ 2.4 μM and IC₉₀ 6.9 μM) and CCR5 (IC₅₀ 3.6 μM and IC₉₀ 11.4 μM) strain infectivity of TZM-bl reporter cells. Furthermore, melittin nanoparticles captured more HIV-1 than blank nanoparticles.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These data illustrate the first proof-of-concept for therapeutic and safe nanoparticle-mediated inhibition of HIV-1 infectivity. Future investigations appear warranted to explore the antiviral prophylactic potential of melittin nanoparticles to capture, disrupt and prevent initial infection with HIV-1 or potentially other enveloped viruses.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Hood</LastName>
                    <ForeName>Joshua L</ForeName>
                    <Initials>JL</Initials>
                    <AffiliationInfo>
                        <Affiliation>Consortium for Translational Research in Advanced Imaging and Nanomedicine, Department of Medicine, Division of Cardiology, Washington University School of Medicine, St Louis, MO, USA. jhood@dom.wustl.edu</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jallouk</LastName>
                    <ForeName>Andrew P</ForeName>
                    <Initials>AP</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Campbell</LastName>
                    <ForeName>Nancy</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ratner</LastName>
                    <ForeName>Lee</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wickline</LastName>
                    <ForeName>Samuel A</ForeName>
                    <Initials>SA</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>R01 AR056223</GrantID>
                    <Acronym>AR</Acronym>
                    <Agency>NIAMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 HL073646</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R21 DK095555</GrantID>
                    <Acronym>DK</Acronym>
                    <Agency>NIDDK NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>U54 CA119342</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2012</Year>
                <Month>09</Month>
                <Day>06</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Antivir Ther</MedlineTA>
            <NlmUniqueID>9815705</NlmUniqueID>
            <ISSNLinking>1359-6535</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D023181">Antimicrobial Cationic Peptides</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D019713">Receptors, CCR5</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D019718">Receptors, CXCR4</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D015728">Receptors, HIV</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>20449-79-0</RegistryNumber>
                <NameOfSubstance UI="D008555">Melitten</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D023181">Antimicrobial Cationic Peptides</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004847">Epithelial Cells</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D057809">HEK293 Cells</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015658">HIV Infections</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015497">HIV-1</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000472">pathogenicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006367">HeLa Cells</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008555">Melitten</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D053758">Nanoparticles</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D019713">Receptors, CCR5</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D019718">Receptors, CXCR4</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015728">Receptors, HIV</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014621">Vagina</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000166">cytology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="accepted">
                <Year>2012</Year>
                <Month>8</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2012</Year>
                <Month>9</Month>
                <Day>06</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2012</Year>
                <Month>9</Month>
                <Day>8</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2012</Year>
                <Month>9</Month>
                <Day>8</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2013</Year>
                <Month>7</Month>
                <Day>31</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.3851/IMP2346</ArticleId>
            <ArticleId IdType="pubmed">22954649</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">4176988</PMID>
        <DateCreated>
            <Year>1968</Year>
            <Month>12</Month>
            <Day>21</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1968</Year>
            <Month>12</Month>
            <Day>21</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0028-4793</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>279</Volume>
                    <Issue>23</Issue>
                    <PubDate>
                        <Year>1968</Year>
                        <Month>Dec</Month>
                        <Day>5</Day>
                    </PubDate>
                </JournalIssue>
                <Title>The New England journal of medicine</Title>
                <ISOAbbreviation>N. Engl. J. Med.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Renal failure and interstitial nephritis due to penicillin and methicillin.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1245-52</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Baldwin</LastName>
                    <ForeName>D S</ForeName>
                    <Initials>DS</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Levine</LastName>
                    <ForeName>B B</ForeName>
                    <Initials>BB</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>McCluskey</LastName>
                    <ForeName>R T</ForeName>
                    <Initials>RT</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gallo</LastName>
                    <ForeName>G R</ForeName>
                    <Initials>GR</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>N Engl J Med</MedlineTA>
            <NlmUniqueID>0255562</NlmUniqueID>
            <ISSNLinking>0028-4793</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D006241">Haptens</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007106">Immune Sera</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D010406">Penicillins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D005719">gamma-Globulins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>Q91FH1328A</RegistryNumber>
                <NameOfSubstance UI="D008712">Methicillin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D058186">Acute Kidney Injury</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001806">Blood Urea Nitrogen</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D004342">Drug Hypersensitivity</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004697">Endocarditis, Bacterial</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004804">Eosinophils</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005455">Fluorescent Antibody Technique</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006041">Goats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006241">Haptens</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007106">Immune Sera</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007668">Kidney</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007678">Kidney Glomerulus</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007684">Kidney Tubules</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007962">Leukocytes</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008712">Methicillin</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009395">Nephritis, Interstitial</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010019">Osteomyelitis</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010406">Penicillins</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011817">Rabbits</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018805">Sepsis</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013203">Staphylococcal Infections</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005719">gamma-Globulins</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1968</Year>
                <Month>12</Month>
                <Day>5</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1968</Year>
                <Month>12</Month>
                <Day>5</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1968</Year>
                <Month>12</Month>
                <Day>5</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">4176988</ArticleId>
            <ArticleId IdType="doi">10.1056/NEJM196812052792302</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>
